Citations

Citations to this article as recorded by  

• Comparison of clinical practice guidelines for chronic hepatitis B: natural history classification and treatment initiation
  Gi-Ae Kim, Won-Mook Choi, Gwang Hyeon Choi, In Hee Kim, Tatsuya Kanto, Ming-Lung Yu, Young-Suk Lim
  Clinical and Molecular Hepatology.2026; 32(3): 1186.     CrossRef

Citations

Citations to this article as recorded by  

• Correspondence to letter to the editor on “Dissecting antibody-mediated natural killer cell effects reveals a cytotoxic CX3CR1+KLRC2-CD16hi subset linked to hepatitis B virus outcomes”
  Zihan Jin, Libo Tang, Yuhao Wang, Shihong Zhong, Yongyin Li
  Clinical and Molecular Hepatology.2026; 32(3): e427.     CrossRef

Citations

Citations to this article as recorded by  

• Correspondence to letter to the editor on “Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0”
  Di Wu, Xiaojing Wang, Weiming Yan, Man-Fung Yuen, Qin Ning
  Clinical and Molecular Hepatology.2026; 32(3): e408.     CrossRef

Citations

Citations to this article as recorded by  

• Current Status and Prospects of Clinical Research on Low-Level Viremia in Chronic Hepatitis B after Treatment
  颜 刘
  Advances in Clinical Medicine.2026; 16(03): 1942.     CrossRef
• New insights into antibody-mediated NK cell immunity in hepatitis B: Editorial on “Dissecting antibody-mediated NK cell effects reveals a cytotoxic CX3CR1⁺KLRC2⁻CD16hi subset linked to HBV outcomes”
  Zuzana Macek Jilkova, Caroline Aspord
  Clinical and Molecular Hepatology.2026; 32(3): 1448.     CrossRef
• Correspondence to editorial on “Dissecting antibody-mediated natural killer cell effects reveals a cytotoxic CX3CR1+KLRC2CD16hi subset linked to hepatitis B virus outcomes”
  Libo Tang, Yuhao Wang, Zihan Jin, Shihong Zhong, Yongyin Li
  Clinical and Molecular Hepatology.2026; 32(3): e384.     CrossRef

Citations

Citations to this article as recorded by  

• Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches
  Prashant Tiwari, Istuti Saraswat, Jyoti Gupta
  Current Microbiology.2026;[Epub]     CrossRef
• Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification
  Tai-Chung Tseng, Shang-Chin Huang, Jia-Horng Kao
  Hepatology Communications.2026;[Epub]     CrossRef
• Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications
  Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G. Duda, Ao Huang, Jian Zhou
  Portal Hypertension & Cirrhosis.2026; 5(1): 65.     CrossRef
• Exploration and optimization of indole derivatives as novel anti-HBV agent with potential TLR7-agonistic effect
  Lihua Yang, Zibin Qiu, Xincheng Li, Jiachen Wei, Yike Ma, Weiqun Yuan, Qiuting Xu, Xiaoke Gu, Jingying Qiu
  Bioorganic & Medicinal Chemistry.2026; 138: 118662.     CrossRef
• Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks
  Kui Wang, Ruchen Zhou
  Clinical and Molecular Hepatology.2026; 32(2): e211.     CrossRef
• Zinc finger protein ZBTB7A suppresses hepatitis B virus replication by attenuating FXRα-mediated HBV transcription and lowering covalently closed circular DNA levels
  Dan Xu, Zhenyu Zhao, Beinu Guo, Zhen Wei, Chen Li, Sichen Luo, Wen Shu, Zhongliang Shen, Mengji Lu, Jiming Zhang, Hecun Zou, Fahong Li, Yong Lin
  Antiviral Research.2026; 252: 106469.     CrossRef
• Hepatitis B Research in Peru, 1988–2023: Geographic Inequities, Thematic Gaps, and Misalignment with Disease Burden
  Jhon Omar Palomino-Tenorio, Obert Marín-Sánchez, Jimmy Ango-Bedriñana, Ruy D. Chacón, Homero Ango-Aguilar
  Pathogens.2026; 15(7): 708.     CrossRef
• Supramolecular Self-Assembly of Lycorine with Glycyrrhizic Acid into a Nanodrug for Safe and Sustained Anti-HBV Therapy
  Hang Sun, Zi-Dong He, Bei-Bei Jia, Bo Yuan, Ling-Chuan Kong, Rui-Xian Xu, Qiong Wang, Wen-Jing Pan, Hao Chen, Shao-Xing Dai, Min Xu
  ACS Applied Bio Materials.2026; 9(15): 7143.     CrossRef
• Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
  Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
  Journal of Gastroenterology and Hepatology.2025; 40(11): 2750.     CrossRef

Citations

Citations to this article as recorded by  

• Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”
  Shang-Chin Huang, Jia-Horng Kao
  Clinical and Molecular Hepatology.2026; 32(1): e117.     CrossRef

Citations

Citations to this article as recorded by  

• Reply to correspondence on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
  Heejoon Jang, Won Kim
  Clinical and Molecular Hepatology.2026; 32(2): e254.     CrossRef

Citations

Citations to this article as recorded by  

• Correspondence to editorial 2 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
  Rui Huang, Mindie H. Nguyen
  Clinical and Molecular Hepatology.2026; 32(1): e85.     CrossRef

Citations

Citations to this article as recorded by  

• Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”
  Shang-Chin Huang, Jia-Horng Kao
  Clinical and Molecular Hepatology.2026; 32(1): e117.     CrossRef
• Correspondence to editorial 1 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
  Rui Huang, Mindie H. Nguyen
  Clinical and Molecular Hepatology.2026; 32(1): e83.     CrossRef
• Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus
  Shang-Chin Huang, Jia-Horng Kao
  Biomedical Journal.2026; 49(3): 100969.     CrossRef
• The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe?
  Shang-Chin Huang, Tai-Chung Tseng
  Gut and Liver.2026; 20(3): 350.     CrossRef
• Insulin Resistance and Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients Under Antiviral Therapy
  Dong Hyun Sinn, Kyung-Ah Kim, Jung Il Lee, Geum-Youn Gwak
  Journal of Korean Medical Science.2026;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis
  Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut
  Hepatology.2026; 83(5): 1273.     CrossRef
• Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”
  Shang-Chin Huang, Jia-Horng Kao
  Clinical and Molecular Hepatology.2026; 32(1): e117.     CrossRef
• Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
  Shang-Chin Huang, Jia-Horng Kao
  Clinical and Molecular Hepatology.2026; 32(1): 423.     CrossRef
• Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection
  Talal K Bhatti, Joseph K Lim
  World Journal of Gastroenterology.2026;[Epub]     CrossRef
• Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor
  Aoyi Li, Yan Han, Guanglin Xiao, Zhiling Deng, Chaojing Wen, Ke Qiu, Taiyu He, Hong Ren
  Journal of Clinical Medicine.2026; 15(5): 1826.     CrossRef
• Antiviral Therapy Reduces Hepatocellular Carcinoma and Cirrhosis Risk in Chinese Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase
  Jian Wang, Zhiyi Zhang, Li Zhu, Tao Fan, Ye Xiong, Shaoqiu Zhang, Chao Jiang, Shengxia Yin, Xin Tong, Juan Xia, Xiaomin Yan, Renling Yao, Yu Shi, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang
  Clinical Gastroenterology and Hepatology.2026;[Epub]     CrossRef
• Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus
  Shang-Chin Huang, Jia-Horng Kao
  Biomedical Journal.2026; 49(3): 100969.     CrossRef
• Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver‐Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy
  Chung‐Feng Huang, Yi‐Hung Lin, Pei‐Chien Tsai, Ming‐Lun Yeh, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yu‐Ju Wei, Nai‐Jen Hou, Ming‐Yen Hsieh, Chao‐Kuan Huang, Tzu‐Chun Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu
  The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
• Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B
  Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng
  Annals of Medicine.2026;[Epub]     CrossRef
• Diagnosing and defining MASLD in people living with chronic hepatitis B
  Emily Martyn, Alejandro Arenas-Pinto, Richard Gilson, Nomathemba Chandiwana, Stuart Flanagan, Douglas MacDonald, Emmanuel A. Tsochatzis, W. D. Francois Venter, Jennifer Manne-Goehler, Philippa C. Matthews
  Communications Medicine.2026;[Epub]     CrossRef
• The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe?
  Shang-Chin Huang, Tai-Chung Tseng
  Gut and Liver.2026; 20(3): 350.     CrossRef
• Insulin Resistance and Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients Under Antiviral Therapy
  Dong Hyun Sinn, Kyung-Ah Kim, Jung Il Lee, Geum-Youn Gwak
  Journal of Korean Medical Science.2026;[Epub]     CrossRef
• Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea
  Hyunjae Shin, Moon Haeng Hur, Yang Hyun Baek, Chun Kyon Lee, Yong Kyun Cho, June Sung Lee, Jae Yoon Jeong, Yong Jin Jung, Ja Kyung Kim, Moon Young Kim, Yeon Seok Seo, Woo Jin Chung, Moon Soo Koh, Jeong-Han Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su
  Gut and Liver.2026; 20(4): 636.     CrossRef
• Differential HCC risk among HBV indeterminate types at baseline and by phase transition
  Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris
  Gut.2025; 74(11): 1873.     CrossRef
• Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment
  Jian Wang, Tao Fan, Zhiyi Zhang, Li Zhu, Shaoqiu Zhang, Ye Xiong, Chun Shan, Chao Jiang, Shengxia Yin, Xin Tong, Renling Yao, Juan Xia, Xiaomin Yan, Yu Shi, Yuxin Chen, Xingxiang Liu, Huali Wang, Haixia Zhang, Chuanwu Zhu, Qun Zhang, Chao Wu, Rui Huang
  Emerging Microbes & Infections.2025;[Epub]     CrossRef
• Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study
  Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats
  eClinicalMedicine.2025; 87: 103407.     CrossRef
• Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
  Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
  Journal of Gastroenterology and Hepatology.2025; 40(11): 2750.     CrossRef
• Multifunctional Metal Composite Hydrogels for Diabetic Wound Therapy
  Shengnan Zhang, Hui Gao, Kevin H. Mayo, Jingang Mo, Le Deng
  Gels.2025; 11(12): 960.     CrossRef

Citations

Citations to this article as recorded by  

• Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients: Correspondence to letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
  Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu
  Clinical and Molecular Hepatology.2026; 32(1): e99.     CrossRef
• Should direct-acting antiviral be considered for all patients with HCV-related hepatocellular carcinoma?: Reply to correspondence on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
  Yan Ling Ong, Apichat Kaewdech, Yu Jun Wong
  Clinical and Molecular Hepatology.2026; 32(1): e109.     CrossRef
• The Clinical Use of Stem Cells in Liver Cancer Treatment: Interactions Between Diet, Metabolic Disease and Hepatic Regeneration
  Julia Coelho Moura, Vincent S Gallicchio
  Journal of Regenerative Medicine and Biology Research.2026; 7(2): 1.     CrossRef

Citations

Citations to this article as recorded by  

• Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients: Correspondence to letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
  Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu
  Clinical and Molecular Hepatology.2026; 32(1): e99.     CrossRef
• Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Correspondence to editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
  Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming-Lung Yu
  Clinical and Molecular Hepatology.2026; 32(1): e68.     CrossRef
• Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
  Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bai
  European Journal of Cancer.2026; 232: 116109.     CrossRef
• Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: a nationwide cohort study”
  Qiong Wang, Zhongqing Qian, Xiaodi Yang, Deyan Chen, Xiaojing Wang, Fuliang Chen
  Clinical and Molecular Hepatology.2026; 32(1): e7.     CrossRef
• Setting the Record Straight: Utility and Outcomes in Patients With HCV Related HCC
  María Fernanda Guerra‐Veloz, Sital Shah, Beatrice Emmanouil, Mia Olsen, Renita George, Sarah Selemani, Paul J. Ross, Ivana Carey, Neha Mehta, Mark Gillyon‐Powell, Kosh Agarwal
  Journal of Viral Hepatitis.2026;[Epub]     CrossRef
• Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR. Authors' Reply
  Yu‐Sheng Lin, Yun‐Yu Chen, Teng‐Yu Lee
  Alimentary Pharmacology & Therapeutics.2026; 63(10): 1439.     CrossRef
• Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
  Yu‐Sheng Lin, Hwai‐I Yang, Teng‐Yu Lee
  Alimentary Pharmacology & Therapeutics.2026; 63(10): 1429.     CrossRef
• Letter: Beyond Association—Operationalising PRS‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
  Yu‐Sheng Lin, Ying‐Cheng Lin, Teng‐Yu Lee
  Alimentary Pharmacology & Therapeutics.2026; 63(10): 1443.     CrossRef
• HIV, Viral Hepatitis, and Schistosomiasis Association with Liver Cancer: A Systematic Review
  Khumbuzile Canham, Pragalathan Naidoo, Sibusiso Senzani, Sayed Shakeel Kader, Zilungile L. Mkhize-Kwitshana
  Microorganisms.2025; 13(12): 2753.     CrossRef

Citations

Citations to this article as recorded by  

• Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
  Haiyu Wang, Jinjun Chen
  Clinical and Molecular Hepatology.2026; 32(1): e58.     CrossRef
• Correspondence to editorial 2 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
  Haiyu Wang, Jinjun Chen
  Clinical and Molecular Hepatology.2026; 32(1): e62.     CrossRef
• Correspondence to editorial 3 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
  Haiyu Wang, Jinjun Chen
  Clinical and Molecular Hepatology.2026; 32(1): e65.     CrossRef
• Reply to correspondence on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
  Mathias Jachs, Mattias Mandorfer
  Clinical and Molecular Hepatology.2026; 32(1): e106.     CrossRef
• Noninvasive Tests for Predicting Decompensation in Compensated Advanced Chronic Liver Disease: A Comprehensive Review
  Audrey Payancé, Pierre‐Emmanuel Rautou, Jérôme Boursier, Laurent Castera, Dominique Valla, Laure Elkrief
  Liver International.2026;[Epub]     CrossRef
• Case Report: Systemic amyloidosis unmasked by progressive hepatomegaly after splenectomy for non-traumatic spleen rupture in a patient with chronic liver disease
  Li-Ping Sheng, Ya-Yun Zhang, Ming Zhang, Bo-Zhi Lin, Rui-Fang Ma, Li-Na Han, Hui Liu, Feng-Qin Hou, Gui-Qiang Wang
  Frontiers in Medicine.2026;[Epub]     CrossRef
• Preventive strategies in hepatology: Role of multiparametric assessment of portal hypertension in chronic liver disease
  Angela Peltec, Ioan Sporea
  World Journal of Gastroenterology.2026;[Epub]     CrossRef
• Ammonia‐to‐Urea Ratio: A Noninvasive First‐Line Tool for Detecting Clinically Significant Portal Hypertension
  Hatime Ouahbi, Vincent Haghnejad, Alexia Audouy, Maël Silva Rodriguez, Françoise Barbé, Jean‐Louis Guéant, Jean‐Pierre Bronowicki, Abderrahim Oussalah
  JGH Open.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
  Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
  Clinical and Molecular Hepatology.2026; 32(1): e55.     CrossRef
• Dynamics and Sensitivity of the Lifecycle of Hepatitis B Virus
  Dmitry Grebennikov, Igor Sazonov, Rostislav Savinkov, Matvey Zakharov, Mark Sorokin, Yakov Mokin, Andreas Meyerhans, Gennady Bocharov
  Pathogens.2026; 15(2): 172.     CrossRef
• ZNF638 represses the transcription of HBV closed circular DNA involving HUSH complex-mediated histone modifications of epigenetic silencing
  Sifan Meng, Jiaqian Li, Yunlong Fang, Binwei Duan, Jing Wang, Yang Si, Feng Li, Qiong Wu, Shan Cheng, Wei Ding
  Cell Communication and Signaling.2026;[Epub]     CrossRef
• Response to letters to editor "Next-Step Paradigms for Hepatitis B Functional Cure: Insights from the Anchor Combination Therapy Trial" and “Critical Appraisal of the Anchor RCT on Entecavir, Peginterferon Alfa-2b, and GM-CSF Combination Therapy”
  Di Wu, Da Huang, Weiming Yan, Qin Ning
  Hepatology International.2026;[Epub]     CrossRef
• Response to letter to editor—Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon
  Jianxia Dong, Sujun Zheng, Xinyue Chen
  Hepatology International.2026;[Epub]     CrossRef
• Mechanisms and management of pegylated interferon-α toxicity in chronic hepatitis B
  Liya Zhu, Fei Peng, Dingfang Pi, Jinzhi Lu
  Frontiers in Immunology.2026;[Epub]     CrossRef
• Long-term antiviral therapy sustains HBsAg decline, increases HBV RNA negativity and enhances the proportion of patients achieving functional cure in chronic hepatitis B
  Ruihan Gao, Shuting Liu, Shiyu Zhang, Xin Zhou, Bin Zhu, Baoju Wang
  Annals of Hepatology.2026; 31(2): 102212.     CrossRef
• Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks
  Kui Wang, Ruchen Zhou
  Clinical and Molecular Hepatology.2026; 32(2): e211.     CrossRef
• A Comparative Study of Entecavir and Tenofovir Alafenamide on Quantitative HBsAg Reduction in Patients With CHB
  Jungnam Lee, Young‐Joo Jin
  Journal of Medical Virology.2026;[Epub]     CrossRef
• Hepatitis B in Children: A Review of Current Knowledge and Future Directions
  Paola Carolina Espin Diaz, Swati Antala
  Current Treatment Options in Pediatrics.2026;[Epub]     CrossRef
• Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications
  Wen Kang, Yu-Shen Liu, Tian-Ping Wang, Shu-Ming Zhang, Yu Li, Ye Zhang
  iLIVER.2026; 5(2): 100235.     CrossRef
• Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controll
  Qiran Zhang, Feng Sun, Shulan Sui, Jianmei Lin, Chuncheng Wu, Jing Yuan, Yingli He, Jia Shang, Tao Han, Ying Zhu, Zuxiong Huang, Chen Chen, Chao Qiu, Xing Wang, Jiming Zhang, Yao Xie, Wenhong Zhang
  Advances in Therapy.2026; 43(8): 3660.     CrossRef
• Case Report: Probable manic episode induced by PEG-IFN α-2b in a chronic hepatitis B patient—multidisciplinary management insights
  Xiao-Cui Wu, Hui Zhou, Lan-Tian Pang, Cui-Lan Tang
  Frontiers in Medicine.2026;[Epub]     CrossRef
• APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update
  Hong You, Rakhi Maiwall, Jing Chen, Sang Hoon Ahn, Kadir Dokmeci, Xiaoguang Dou, Manal El-Sayed, Jian-Gao Fan, Rino Gani, Zhiliang Gao, Jacob George, Hasmik Ghazinian, George Goh, Saeed Hamid, Jinlin Hou, Shang-Chin Huang, Dong Ji, Jidong Jia, Tatsuo Kand
  Hepatology International.2026;[Epub]     CrossRef
• PD-1/PD-L1 blockade as part of combination strategies toward functional cure of chronic hepatitis B
  Mei Li, Dandan Feng, Juanjuan Shi, Shuangsuo Dang, Xiaoli Jia, Wenjun Wang
  Frontiers in Immunology.2026;[Epub]     CrossRef
• Comment on the expert consensus on treatment approaches for achieving functional cure in chronic hepatitis B: Letter to the editor on “Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0”
  Seng-Gee Lim, Melanie Paff
  Clinical and Molecular Hepatology.2026; 32(3): e285.     CrossRef
• Hepatitis B core-related antigen as a multifaceted biomarker in chronic hepatitis B: implications for immune activity and hepatocellular carcinoma prediction
  Kwon Yong Tak, Seok Hwan Kim, Myeong Jun Song
  The Korean Journal of Internal Medicine.2026; 41(4): 636.     CrossRef
• Optimizing pegylated interferon α‐2b consolidation duration and developing a recurrence prediction model after functional cure based on updated definition in chronic hepatitis B
  Yuchen Peng, Liping Liu, Xiaoping Wu
  European Journal of Medical Research.2026;[Epub]     CrossRef
• Advances in Viral Markers for Predicting Functional Cure of Chronic Hepatitis B
  Xinrong Lu, Xin Yang, Qishui Ou, Zhen Xun
  Portal Hypertension & Cirrhosis.2026;[Epub]     CrossRef
• Noninvasive models for patient selection and Early response monitoring of interferon therapy for HBsAg clearance in patients with chronic hepatitis B
  Zhaopei Guo, Yan Pan, Lin Lin, Xiangjun Tang, Weiquan You, Fengling Fang, Hongyan Guo, Yiming Zhong, Dina Haishaer, Lu Lai, Yue Shi, Yutong Li, Dong Huang, Kaixin Chen, Yongjie Xu, Ni Lin, Tianbin Chen, Yongbin Zeng, Qishui Ou, Ya Fu
  BMC Infectious Diseases.2026;[Epub]     CrossRef
• Residual viral expression in siRNA-treated HBV-replicating cell and mouse models
  Mingzhu Xu, Yuyan Qian, Ziyang Song, Haiyu Wang, Lei Yue, Jiangxia Liu, Yaming Li, Wenjing Zai, Zhenghong Yuan, Jieliang Chen
  Antiviral Research.2025; 240: 106210.     CrossRef
• Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection
  Yiwen Shu, Sumeng Li, Yanqin Du, Xin Zheng
  Frontiers in Immunology.2025;[Epub]     CrossRef
• Quantitatively Evaluate the Improvement of Functional Cure for the Quality of Life of Chronic Hepatitis B Cases: Evidence from a Cross-Sectional Study in China
  Sihui Zhang, Zhiliang Gao, Hui Li, Yi Kang, Lei Fu, Xuebing Chen, Xiaoyuan Xu, Xinyue Chen, Hui Zhuang, Hui Zheng, Fuqiang Cui
  Healthcare.2025; 13(20): 2590.     CrossRef
• Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study
  Yong-Hong Wang, Ya-Chao Tao, Meng-Lan Wang, Cheng-Run Song, Jiang-Nan Peng, En-Qiang Chen
  Journal of Virus Eradication.2025; 11(4): 100617.     CrossRef
• An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection
  Ze-Ao Huang, Yang Yang, Shuo Yang, Guang-Shen Ji, Rui Fu, Zhi-Kang Tian, Yu-Cheng Wu, Geng-Shen Song
  Nature Communications.2025;[Epub]     CrossRef
• A Study on Serum Protein Tracking in Patients with Low Levels of HBsAg Undergoing Treatment for Chronic Hepatitis B with a Combination of Tenofovir Disoproxil Fumarate and Pegylated Interferon
  Yimin Chen, Min Deng, Mingkai Tong, Peixia Lin, Hua Xuan, Dahai Wei
  Hepatitis Monthly.2025;[Epub]     CrossRef
• Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study
  Jianxia Dong, Shan Ren, Jing Zhao, Pengxuan Wu, Haitian Yu, Yao Xie, Junliang Fu, Xiaorong Mao, Zhiliang Gao, Bingliang Lin, Qingfa Ruan, Yongfang Jiang, Xiulan Xue, Yueyong Zhu, Haidong Zhao, Haifang Cao, Xinyue Chen, Sujun Zheng
  Virology Journal.2025;[Epub]     CrossRef
• Functional cure of chronic hepatitis B virus infection: current therapeutic regimens
  Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao
  Hepatoma Research.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TOR
  Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin
  Clinical and Molecular Hepatology.2025; 31(2): e169.     CrossRef

Citations

Citations to this article as recorded by  

• Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure
  Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen
  Gut.2026; 75(1): 119.     CrossRef
• Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
  Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
  Clinical and Molecular Hepatology.2026; 32(1): e55.     CrossRef
• Viral manipulation of host cell glutamine metabolism and glutamine rewiring in hepatic diseases: Editorial on “Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalentl
  Mehrangiz Dezhbord, Kyun-Hwan Kim
  Clinical and Molecular Hepatology.2026; 32(1): 385.     CrossRef
• Targeting the innate immune system in treating hepatitis B: prospects for functional cure
  Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
  Clinical and Molecular Hepatology.2026; 32(1): 184.     CrossRef
• Large-scale screening of HBV epitopes restricted by multiple prevalent HLA-B/C allotypes and routine detection of HBV-specific T cells in CHB patients
  Yandan Wu, Yu Zhao, Ruixue Ji, Pinqing Li, Huijuan Chen, Fangping Yue, Yi Wu, Jie Qiu, Chuanlai Shen
  Frontiers in Immunology.2026;[Epub]     CrossRef
• Group-based trajectory modeling for declines in hepatitis B surface antigen over time accurately identifies chronic hepatitis B patients achieving functional cure: a single-center cohort study in China
  Yuchen Peng, Liping Liu, Xiaoping Wu
  Annals of Medicine.2026;[Epub]     CrossRef
• Risk Prediction of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance in Patients With Chronic Hepatitis B
  Shuaibing Ying, Jinyao Dai, Qiudan Zhang, Yujing Wang, Yina Yu, Zhijuan Zhang, Shaohua Dong, Yichun Zhang, Haoyang Hu, Yuqi Hong, Yi Liu, Yuqi Guo, Haomin Yan, Yunqing Qiu, Yan Lou
  Alimentary Pharmacology & Therapeutics.2026; 64(1): 50.     CrossRef
• Sodium taurocholate cotransporting polypeptide in HBV-related diseases: from underlying mechanisms to targeted therapies
  Qiang Xie, Qingbo Liu, Xin Zheng, Leilei Fu, Hussein H. Aly, Bo Liu
  Drug Discovery Today.2026; 31(3): 104664.     CrossRef
• Exploration and optimization of indole derivatives as novel anti-HBV agent with potential TLR7-agonistic effect
  Lihua Yang, Zibin Qiu, Xincheng Li, Jiachen Wei, Yike Ma, Weiqun Yuan, Qiuting Xu, Xiaoke Gu, Jingying Qiu
  Bioorganic & Medicinal Chemistry.2026; 138: 118662.     CrossRef
• CD16+ γδ T cells mediate antibody-dependent cellular cytotoxicity and associate with viral control in chronic hepatitis B virus infection
  Paulina E Schröter, Katja Steppich, Laura Fernández Carrera, Zheng Song, Sebastian Klein, Roni Souleiman, Melanie Urbanek-Quaing, Ayesha D Lietzau, Ansgar Schnieders, Erich Freyer, Birgit Bremer, Ximena León-Lara, Vicente Almeida, Rodrigo Gutierrez Jaureg
  Gut.2026; : gutjnl-2025-337640.     CrossRef
• Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers
  Liping Xu, Huaqun Zhang, Bingchen Jiang, Yuanying Jiang, Hui Lu
  Pharmaceutics.2026; 18(4): 446.     CrossRef
• Repurposing Product Nkabinde for Hepatitis B Virus Therapy: A Network Pharmacology and Molecular Docking Investigation
  Samuel Chima Ugbaja, Siphathimandla Authority Nkabinde, Magugu Nkabinde, Nceba Gqaleni
  Pharmaceuticals.2026; 19(4): 627.     CrossRef
• Functionalized locked nucleic acid system for targeted inhibition of hepatitis B virus C gene in transgenic models
  Wu-Jun Wei, Huai-Jun Luo, Liu-Mei Qin, Jin-Ling Li, Nuo Zhou, Cai-Xia Ling, Jun-Xia Pu, Yi-Bin Deng
  Arabian Journal of Chemistry.2026; 0: 1.     CrossRef
• Droplet Digital PCR Measurement of HBV DNA in On‐Treatment Chronic HBV Patients: Association With HCC Development and Outcomes
  Rex Wan‐Hin Hui, Danny Ka‐Ho Wong, James Fung, Ka‐Shing Cheung, Wai‐Kay Seto, Lung‐Yi Mak, Man‐Fung Yuen
  Journal of Viral Hepatitis.2026;[Epub]     CrossRef
• New insights into antibody-mediated NK cell immunity in hepatitis B: Editorial on “Dissecting antibody-mediated NK cell effects reveals a cytotoxic CX3CR1⁺KLRC2⁻CD16hi subset linked to HBV outcomes”
  Zuzana Macek Jilkova, Caroline Aspord
  Clinical and Molecular Hepatology.2026; 32(3): 1448.     CrossRef
• Correspondence to editorial on “Dissecting antibody-mediated natural killer cell effects reveals a cytotoxic CX3CR1+KLRC2CD16hi subset linked to hepatitis B virus outcomes”
  Libo Tang, Yuhao Wang, Zihan Jin, Shihong Zhong, Yongyin Li
  Clinical and Molecular Hepatology.2026; 32(3): e384.     CrossRef
• Multiplex gene editing to target the roots of hepatitis B virus infection
  Anuj Kumar, Fabien Zoulim
  Molecular Therapy Nucleic Acids.2026; 37(3): 103026.     CrossRef
• Reply to: “ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFNα based therapy”
  Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
  Journal of Hepatology.2025; 82(5): e228.     CrossRef
• Expanding treatment indications in chronic hepatitis B: Should we treat all patients?
  Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
  Hepatology International.2025; 19(2): 304.     CrossRef
• Combining therapeutic agents to target the immune systems of hepatitis B patients: what do we need to consider?
  Shang-Chin Huang, Jia-Horng Kao
  Expert Review of Gastroenterology & Hepatology.2025; 19(4): 371.     CrossRef
• Efficacy of Antiviral Therapy in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase: A Systematic Review and Meta‐Analysis
  Yuting Diao, Yueying Zeng, Zhihao Huang, Chunfang You, Kevork M. Peltekian
  Canadian Journal of Gastroenterology and Hepatology.2025;[Epub]     CrossRef
• Hepatitis B: Neue therapeutische Ansätze für eine funktionelle Heilung
  Markus Cornberg, Ulrike Protzer
  Deutsches Ärzteblatt Online.2025;[Epub]     CrossRef
• Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability
  Yurong Yang, Fuling Xiao, Jianping Zuo, Li Yang, Youhong Hu, Wuhong Chen
  Bioorganic & Medicinal Chemistry.2025; 128: 118259.     CrossRef
• Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies
  Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
  Hepatology International.2025; 19(4): 704.     CrossRef
• Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure
  Ana Verma, Raymond T. Chung
  Current Opinion in HIV and AIDS.2025; 20(5): 449.     CrossRef
• Challenges and advances in clinical cure of chronic hepatitis B
  Xu-Ling Liu, Yu-Lang Jiang, Ming-Yu Sun
  World Chinese Journal of Digestology.2025; 33(9): 693.     CrossRef
• Small molecule HBV RNA destabilizing drugs: Drugs of the future or compounds from the past?
  Timothy M. Block, Dimitar Gotchev, Yanming Du
  Antiviral Research.2025; 244: 106288.     CrossRef
• Global strategies and actions to eliminate hepatitis B virus infection
  Chih-Lin Lin, Jia-Horng Kao
  Clinical and Molecular Hepatology.2025; 31(4): 1197.     CrossRef
• Morphometric and structural dynamic parameters of hepatitis viruses: implications for therapeutic and vaccine failure
  Saganuwan Alhaji Saganuwan
  Discover Viruses.2025;[Epub]     CrossRef
• Functional cure of chronic hepatitis B virus infection: current therapeutic regimens
  Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao
  Hepatoma Research.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TOR
  Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin
  Clinical and Molecular Hepatology.2025; 31(2): e169.     CrossRef

Citations

Citations to this article as recorded by  

• Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
  Mirko Zoncapè, Emmanuel A. Tsochatzis
  Clinical and Molecular Hepatology.2025; 31(1): e117.     CrossRef

Citations

Citations to this article as recorded by  

• Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
  Mirko Zoncapè, Emmanuel A. Tsochatzis
  Clinical and Molecular Hepatology.2025; 31(1): e117.     CrossRef
• Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
  Young-Joo Jin, Seung Up Kim
  Clinical and Molecular Hepatology.2025; 31(1): e55.     CrossRef
• Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
  Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
  Journal of Gastroenterology and Hepatology.2025; 40(11): 2750.     CrossRef

Citations

Citations to this article as recorded by  

• Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment
  Ina Bergheim, Jean Francois Cadranel, Jianguo Chen, Wenxing Ding, Robert Eferl, Carmen Garcia-Ruiz, Hartmut Jaeschke, Firouzeh Kazerouni, Amedeo Lonardo, Derek A. Mann, Nahum Méndez-Sánchez, Camelia Mokhtari, Han Moshage, Chiara Raggi, Pavel Strnad, Oren
  Exploration of Digestive Diseases.2026;[Epub]     CrossRef
• Optimizing hepatitis C micro-elimination in forensic psychiatric settings: Cost-effectiveness of screening strategies in Korea
  Gyeongseon Shin, Sang Hoon Ahn, Hankil Lee, Beom Kyung Kim
  Journal of Infection and Public Health.2026; 19(9): 103331.     CrossRef

Citations

Citations to this article as recorded by  

• Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”
  Gi-Ae Kim, Seung Won Choi, Young-Suk Lim
  Clinical and Molecular Hepatology.2025; 31(1): e108.     CrossRef

Citations

Citations to this article as recorded by  

• Chronic Hepatitis B Infection: Patient Guidance
  Lung‐Yi Mak, Jimmy Che‐To Lai, Ken Liu, Rashid Lui, Sakkarin Chirapongsathorn, Kuo Chao Yew, Mara Teresa Panlilio, Cosmas Rinaldi Adithya Lesmana, Ruveena Bhavani Rajaram, Liang Shen, Desmond Cheung, Lung‐Fai Wong, Hye Won Lee, Madhumita Premkumar, Anand 
  Journal of Gastroenterology and Hepatology.2026; 41(1): 61.     CrossRef
• APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update
  Hong You, Rakhi Maiwall, Jing Chen, Sang Hoon Ahn, Kadir Dokmeci, Xiaoguang Dou, Manal El-Sayed, Jian-Gao Fan, Rino Gani, Zhiliang Gao, Jacob George, Hasmik Ghazinian, George Goh, Saeed Hamid, Jinlin Hou, Shang-Chin Huang, Dong Ji, Jidong Jia, Tatsuo Kand
  Hepatology International.2026;[Epub]     CrossRef
• Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
  Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
  Health Science Reports.2025;[Epub]     CrossRef
• Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis
  Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K
  Journal of Gastroenterology and Hepatology.2025; 40(6): 1595.     CrossRef
• Assessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers?
  Deniz Borcak, Zuhal Yesilbag, Yusuf Emre Ozdemir, Adile Sevde Demir, Esra Salim Dogdas, Aysegul Inci Sezen, Esra Canbolat Unlu, Sevtap Senoglu, Hayat Kumbasar Karaosmanoglu, Kadriye Kart Yasar
  Journal of Clinical Medicine.2025; 14(22): 8164.     CrossRef
• Vibration-Controlled Transient Elastography in Chronic Liver Disease: Current Research Insights
  Ho Soo Chun
  Clinical Ultrasound.2025; 10(2): 69.     CrossRef
• Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease
  Jung Hwan Yu
  The Korean Journal of Medicine.2024; 99(5): 232.     CrossRef
• Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography
  Mi Na Kim
  The Korean Journal of Gastroenterology.2024; 84(5): 201.     CrossRef
• Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography
  Han Ah Lee
  Clinical Ultrasound.2024; 9(2): 70.     CrossRef

Citations

Citations to this article as recorded by  

• Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
  Haiyu Wang, Jinjun Chen
  Clinical and Molecular Hepatology.2026; 32(1): e58.     CrossRef
• Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-Male-Albumin-Bilirubin-Platelet (aMAP) and Liver Stiffness Assessed by Vibration-Controlled Transient Elastography
  Hye Yeon Chon, Hyung Joon Yim, Seok-Jae Heo, Su Jong Yu, Ja Kyung Kim, Sang Hoon Ahn, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip, Sang Gyune Kim, Yeon Seok Seo, Seung Up Kim
  Clinical Gastroenterology and Hepatology.2026; 24(7): 1897.     CrossRef
• Toward Precise Risk Stratification after the Functional Cure of Chronic Hepatitis B
  Moon Haeng Hur
  The Korean Journal of Gastroenterology.2026; 86(2): 71.     CrossRef
• Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B
  Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng
  Annals of Medicine.2026;[Epub]     CrossRef
• Hepatitis B Virus and Hepatocellular Carcinoma: Risk-Based Surveillance Strategies
  Abdelrahman M. Attia, Jessica Liu, Walid S Ayoub, Yun Wang, Aarshi Vipani, Paul Martin, Hyunseok Kim, Ju Dong Yang
  Current Hepatology Reports.2026;[Epub]     CrossRef
• Four-dimensional flow MRI for identifying high-risk esophageal varices: a comparison and combination with spleen volume and splenic extracellular volume fraction
  Xiaohuan Li, Yuhan Zhang, Zhiyuan Chen, Ke Wei, Yan Zhang, Xiying Zhao, Shuping Zhang, Ruhang Huang, Yupin Liu, Dongjing Zhou
  Insights into Imaging.2026;[Epub]     CrossRef
• The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: S
  Mirko Zoncapè, Emmanuel A. Tsochatzis
  Clinical and Molecular Hepatology.2025; 31(1): 268.     CrossRef
• Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
  Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
  Health Science Reports.2025;[Epub]     CrossRef
• A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B
  Jiwon Yang, Mark D. Muthiah, Won-Mook Choi
  Current Hepatology Reports.2025;[Epub]     CrossRef
• Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis
  Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K
  Journal of Gastroenterology and Hepatology.2025; 40(6): 1595.     CrossRef
• Discovering the metabolic pathway of liver disease by breath mass spectrometry combined with machine learning
  Xuanzhu Li, Wenbo Zhang, Tongtong Yang, Ying Zhang, Rui Su
  Journal of Pharmaceutical and Biomedical Analysis.2025; 265: 116988.     CrossRef
• Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C
  Beom Kyung Kim
  Journal of Gastroenterology and Hepatology.2025; 40(8): 1855.     CrossRef
• EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection
  Shichuan Tang, Tingfeng Huang, Ruijing Tang, Kongying Lin, Cong Luo, Yubing Shen, Kailing Zhang, Yidan Tang, Jie Kong, Zhenwei Chen, Jun Fu, Qizhu Lin, Luobin Guo, Yeye Wu, Yuntong Li, Jianxi Zhang, Zhenghong Sun, Penghui You, Daichang Zhang, Yanxin Chen,
  Gut.2025; : gutjnl-2025-335449.     CrossRef
• The Evolving Application of Ultrasound in the Precision Management of Small Hepatocellular Carcinoma
  Xin Guan, Xinyuan Hu, Hong Han, Dezhi Zhang, Huixiong Xu
  Advanced Ultrasound in Diagnosis and Therapy.2025; 9(4): 375.     CrossRef
• Transient Elastography and Fibroscan: Stethoscope of a Hepatologist in Today’s World
  Sajid Jalil, Mangesh Pagadala, Nicholas Dunn, Hanna Blaney, Mohamed Elfeki, Nimish Thakral, Ashwani K. Singal
  Current Hepatology Reports.2025;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Navigating the Viral Hepatitis Drug Landscape: New Discoveries and Enduring Challenges. A Narrative Review
  He-ming Sun, Xing-yu Wang, Hong-qin Xu, Yan-hang Gao
  Infectious Diseases and Therapy.2026; 15(4): 959.     CrossRef
• Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease
  Chunting Zhu, Jie Yang, Yu Sheng, Min Fang
  Frontiers in Immunology.2026;[Epub]     CrossRef
• Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis
  Jing Chen, Dong Ji, Jidong Jia, Hui Zhuang, Xinxin Zhang, Fu-Sheng Wang, Wenhong Zhang, Xiaoguang Dou, Tawesak Tanwandee, Shiv Kumar Sarin, Rakhi Maiwall, Manoj Kumar, George Boon-Bee Goh, Hasmik Ghazinyan, Anuchit Chutaputti, Pei-Jer Chen, Hong You, Ming
  Hepatology International.2025; 19(4): 773.     CrossRef
• Mise à jour concernant le traitement des hépatites virales
  Marie Ongaro, Francesco Negro
  Schweizer Gastroenterologie.2025; 6(2): 46.     CrossRef
• Advances in the computational development of hepatitis B virus capsid assembly modulators
  Ke Liu, Shaoqing Du, Weiqiao Deng, Zongjin Qu, Xueping Hu
  Drug Discovery Today.2025; 30(10): 104458.     CrossRef
• Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients”
  Hae Lim Lee, Jeong Won Jang
  Clinical and Molecular Hepatology.2024; 30(4): 692.     CrossRef

Citations

Citations to this article as recorded by  

• Current status and challenges of therapeutic targets, novel drugs and delivery systems for hepatitis B: how far to our goal?
  Yanmei Liao, Fei Lv, Mei Zhou, Jie Shen, Tianwen Quan
  Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
• Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease
  Chunting Zhu, Jie Yang, Yu Sheng, Min Fang
  Frontiers in Immunology.2026;[Epub]     CrossRef
• Correspondence to letter to the editor on “Dissecting antibody-mediated natural killer cell effects reveals a cytotoxic CX3CR1+KLRC2-CD16hi subset linked to hepatitis B virus outcomes”
  Zihan Jin, Libo Tang, Yuhao Wang, Shihong Zhong, Yongyin Li
  Clinical and Molecular Hepatology.2026; 32(3): e427.     CrossRef
• Hepatitis B virus infection and its treatment in Eastern Ethiopia
  Tatsuo Kanda, Reina Sasaki-Tanaka, Atsunori Tsuchiya, Shuji Terai
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Functional Cure for Hepatitis B Virus: Challenges and Achievements
  Oren Shechter, Daniel G. Sausen, Harel Dahari, Andrew Vaillant, Scott J. Cotler, Ronen Borenstein
  International Journal of Molecular Sciences.2025; 26(8): 3633.     CrossRef
• Advances in the computational development of hepatitis B virus capsid assembly modulators
  Ke Liu, Shaoqing Du, Weiqiao Deng, Zongjin Qu, Xueping Hu
  Drug Discovery Today.2025; 30(10): 104458.     CrossRef
• HBc: the multifunctional architect of HBV replication, immune evasion, and therapeutic innovation
  Yujia Zhu, Hongxiao Song, Fengchao Xu, Mian Huang, Guangyun Tan
  Frontiers in Immunology.2025;[Epub]     CrossRef
• Multisite Occupancy and Multidimensional Optimization: Design and Evaluation of Piperazine-Thioureidobenzamide Derivatives as Potent HBV Capsid Assembly Modulators
  Minghui Liang, Yutong Dou, Jian Zhang, Zechun Yang, Yuanyuan Liu, Mei Wang, Yiyan Mao, Lindan Guan, Aixin Li, Yuqing Cai, Yan Wang, Peng Xue, Lei Zhang, Zhuanchang Wu, Xinyong Liu, Peng Zhan, Haiyong Jia
  Journal of Medicinal Chemistry.2025; 68(22): 24358.     CrossRef
• Linvencovir: Paving the way for functional cure in hepatitis B
  Jiwon Yang, Jonggi Choi
  Clinical and Molecular Hepatology.2024; 30(2): 164.     CrossRef
• Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
  Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim
  Clinical and Molecular Hepatology.2024; 30(3): 539.     CrossRef
• Novel mechanistic insights – A brand new Era for anti-HBV drugs
  Weiping Lyu, Haoming Qin, Qi Li, Dehua Lu, Cheng Shi, Kangchen Zhao, Shengran Zhang, Ruohan Yu, Huiying Zhang, Xiaonan Zhou, Sitian Xia, Liangren Zhang, Xiaoqian Wang, Xiaowei Chi, Zhenming Liu
  European Journal of Medicinal Chemistry.2024; 279: 116854.     CrossRef

Citations

Citations to this article as recorded by  

• Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial
  Rong Fan, Rui Deng, Qing Xie, Fang Wang, Xieer Liang, Hong Ma, Huiying Rao, Yanhang Gao, Chunxiu Zhong, Qing Guo, Sheng Shen, Ya Xu, Xingyu Lu, Hongbo Gao, Honglian Bai, Xiaoguang Dou, Jian Sun
  Clinical Gastroenterology and Hepatology.2026; 24(6): 1611.     CrossRef
• Similar hepatic outcome by SGLT2i vs. DPP4i for at-risk cohort with CHB & T2DM: A nationwide target trial emulation study
  Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
  Annals of Hepatology.2026; 31(1): 102175.     CrossRef
• Mitochondrial metabolic remodeling predicts therapeutic response to PegIFN-α in chronic hepatitis B
  Yingying Zhang, Xiu Han, Chengyu Xu, Yahui Song, Jinghan Zhu, Ruoran Zhou, Yiling Chen, Mingming Liu, Junchi Xu, Xiangwei Wu, Qingzhen Han, Zutao Chen
  Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
• Risk factors and predicted model for clinical relapse after antiviral therapy cessation in chronic hepatitis B patients: a retrospective real-world data analysis
  Xiaoli Zhang, Meiyan Mao, Yunxia Zhang, Xiuxi Li
  BioMedical Engineering OnLine.2026;[Epub]     CrossRef
• Clinical utility of hepatitis B core-related antigen in chronic hepatitis B infection: diagnostic, prognostic, and therapeutic implications
  Bukhari Isah Shuaib, Usman Linda Itunu, Aminat Daud
  Egyptian Liver Journal.2026;[Epub]     CrossRef
• Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss
  Ying‐Nan Tsai, Jia‐Ling Wu, Cheng‐Hao Tseng, Tzu‐Haw Chen, Ying‐Chu Chung, Mindie H. Nguyen, Jaw‐Town Lin, Katsuya Nagaoka, Yasuhito Tanaka, Yao‐Chun Hsu
  Alimentary Pharmacology & Therapeutics.2026; 64(1): 89.     CrossRef
• Low-level hepatitis B surface antigen by ECLIA stratifies early relapse risk in patients with interferon-based HBV functional cure
  Xiangyong Li, Baoer Wu, Huaping Xie, Hao Hu, Ting Liu, Xu You, Yanhua Bi, Yurong Gu
  Frontiers in Immunology.2026;[Epub]     CrossRef
• Hepatitis B core-related antigen as a multifaceted biomarker in chronic hepatitis B: implications for immune activity and hepatocellular carcinoma prediction
  Kwon Yong Tak, Seok Hwan Kim, Myeong Jun Song
  The Korean Journal of Internal Medicine.2026; 41(4): 636.     CrossRef
• Early HBcrAg and Anti‐HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials
  Edo J. Dongelmans, Jordan J. Feld, André Boonstra, Sylvia M. Brakenhoff, David Wong, Colina Yim, Mark Claassen, Pieter Honkoop, Bettina E. Hansen, Robert A. de Man, Scott Fung, Thomas Berg, Florian van Bömmel, Harry L. A. Janssen, Milan J. Sonneveld
  Alimentary Pharmacology & Therapeutics.2025; 61(3): 570.     CrossRef
• Achieving chronic hepatitis B functional cure: Factors and potential mechanisms
  Jiarui Zheng, Zilong Wang, Linxiang Huang, Zixuan Qiu, Yandi Xie, Suzhen Jiang, Bo Feng
  Virus Research.2025; 351: 199507.     CrossRef
• Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure
  Yue Qiu, Qiao Tang, Xiao-Qing Liu, Yun-Ling Xue, Yi Zeng, Peng Hu
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
  Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
  Liver International.2025;[Epub]     CrossRef
• Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study
  Yong-Hong Wang, Ya-Chao Tao, Meng-Lan Wang, Cheng-Run Song, Jiang-Nan Peng, En-Qiang Chen
  Journal of Virus Eradication.2025; 11(4): 100617.     CrossRef
• Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen
  Yoshihiko Yano, Itsuko Sato, Takamitsu Imanishi, Ryutaro Yoshida, Takanori Matsuura, Yoshihide Ueda, Yuzo Kodama
  Diagnostics.2024; 14(7): 728.     CrossRef
• Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”
  Yun-Fan Liaw
  Clinical and Molecular Hepatology.2024; 30(2): 269.     CrossRef
• Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen
  Chen-Te Huang, Tai-Chung Tseng
  Clinical and Molecular Hepatology.2024; 30(2): 154.     CrossRef
• Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research
  Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu
  Clinical and Molecular Hepatology.2024; 30(2): 276.     CrossRef
• Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring
  Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu
  Clinical and Molecular Hepatology.2024; 30(2): 293.     CrossRef
• A critical review of diagnostic and prognostic markers of chronic hepatitis B infection
  Shuaibu Abdullahi Hudu, Sa’adatu Haruna Shinkafi, Abdulgafar Olayiwola Jimoh
  Medical Review.2024; 4(3): 225.     CrossRef
• Virological markers for clinical trials in chronic viral hepatitis
  Jean-Michel Pawlotsky
  JHEP Reports.2024; 6(11): 101214.     CrossRef

Citations

Citations to this article as recorded by  

• Artificial intelligence prognostication of liver disease using imaging
  Manil D Chouhan, Kate McLean, James A Thomas, Jason Dowling
  British Journal of Radiology.2026; 99(1182): 1036.     CrossRef
• The atlas of abdominal organ remodeling in hepatocellular carcinoma patients: An artificial intelligence-based multicenter imaging study
  Yusheng Guo, Xiaona Fu, Tianxiang Li, Ning Wang, Shanshan Jiang, Shanmei Li, Xiaofang Guo, Rundong Wang, Shichao Long, Mengsi Li, Qiuping Liu, Kai Zhao, Yangyang Xie, Xuejun Chen, Lixia Wang, Chuansheng Zheng, Lian Yang
  Med.2026; 7(7): 101176.     CrossRef
• Dynamic changes in visceral fat density and skeletal muscle index predict new-onset decompensation in chronic hepatitis B-related cirrhosis
  Xiaoyue Zhang, Zheyu Li, Cuifang He, Shangwen Hu, Yirui Hu, Huixia Zhang, Qianhui Gao, Wanchun Qiu, Wenqiang He, Zhenxia Huang, Meiling Zhang, Jiale Lu, Liting Zhang, Junfeng Li
  Hepatobiliary Communications.2026; 1(1): 100003.     CrossRef
• Routine laboratory model for identifying significant fibrosis in chronic hepatitis B
  Ting-Ting Wang, Yi-Li Chu, Yi-Qiang Lou, Rou-Yi Yang, Mao-Mao Pu, Lian-Jiang Shan, Lu Huang, Shan-Shan Chen, Hai-Jun Huang
  World Journal of Hepatology.2026;[Epub]     CrossRef
• Automated analysis of abdominal body composition using MRI: algorithm development and validation via CT comparison
  S.K. Jeon, I. Joo, J.M. Lee, J.-M. Kim, H.-J. Chung, S.J. Park
  Clinical Radiology.2026; 100: 107437.     CrossRef
• Reply to: “A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?”
  Moon Haeng Hur, Jeong-Hoon Lee
  Journal of Hepatology.2025; 82(3): e143.     CrossRef
• Early prediction of adverse outcomes in liver cirrhosis using a CT-based multimodal deep learning model
  Nanai Xie, Yiwen Liang, Zixin Luo, Jing Hu, Ruiquan Ge, Xiang Wan, Changmiao Wang, Guannan Zou, Feng Guo, Yi Jiang
  Abdominal Radiology.2025; 51(1): 137.     CrossRef
• Correspondence to editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”
  Xiaoqian Xu, Hong You, Jidong Jia, Yuanyuan Kong
  Clinical and Molecular Hepatology.2024; 30(4): 994.     CrossRef
• Deep learning assisted biomarker development in patients with chronic hepatitis B: Editorial on “Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection”
  Yong Eun Chung
  Clinical and Molecular Hepatology.2024; 30(4): 669.     CrossRef
• Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B pati
  Beom Kyung Kim
  Clinical and Molecular Hepatology.2024; 30(4): 656.     CrossRef
• Assessment of body composition and prediction of infectious pancreatic necrosis via non-contrast CT radiomics and deep learning
  Bingyao Huang, Yi Gao, Lina Wu
  Frontiers in Microbiology.2024;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Impact of Add‐On Hepatobiliary Abbreviated Magnetic Resonance Imaging on Ultrasound Hepatoma Surveillance for Liver Cirrhosis‐ a Randomized Study
  Jing‐Houng Wang, Hsin‐You Ou, Yi‐Hao Yen, Chao‐Hung Hung, Sheng‐Nan Lu
  The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
• Clinical outcomes of carbon-ion radiotherapy for residual or recurrent hepatocellular carcinoma after transarterial chemoembolization
  Y. Sekiguchi, K. Shibuya, S. Tomogane, Y. Miyasaka, S. Kakizaki, M. Okamoto, K. Araki, K. Shirabe, T. Ohno
  ESMO Gastrointestinal Oncology.2026; 11: 100280.     CrossRef
• Survival and safety outcomes of hepatectomy versus ablation in hepatocellular carcinoma within Milan criteria and clinically significant portal hypertension: a systematic review and meta-analysis
  Yong-Hao Wen, Yu-Min Yang, Jing-Xin Yan, Peng Gu, Yan-Qi Tai, Jin-Yu Li, Yun-Long Duan, Man-Jun Deng, Hai-Ning Fan
  International Journal of Surgery.2026; 112(4): 10642.     CrossRef
• Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach
  Sun Young Yim, Hayeon Kim, Tae Hyung Kim, Sang-Hee Kang, Youngwoo Lee, Eunho Choi, Yang Jae Yoo, Seong Hee Kang, Young-Sun Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kyung Suk Yang, Yitao Tang, Bowha Sohn, Yun Seong Jeong, Hyewon P
  JHEP Reports.2026; 8(4): 101742.     CrossRef
• Targeting Wnt3a and Loxl2 Synergistically Induces Ferroptosis in Liver Cancer Stem Cells and Suppresses Tumorigenesis
  Guanghui Ren, Qingwei Cong, Jing Wang, Wenyue Gao, Yunpeng Guan, Lianxin Zhu, Ying Zhu
  Cancer Science.2026; 117(4): 972.     CrossRef
• SPARC: A programmable molecular diagnostic platform based on a signal-triggered, self-supplied crRNA and tiered PER-transcription-CRISPR cascade for early detection of hepatocellular carcinoma
  Xinying Chang, Cong Han, Haishuo Ji, Zhe Zeng, Jingyi Yang, Qirui Liu, Chao Jia, Lili Zhao, Chunlei Zhou, Shujia Chen, Wolfgang Knoll, Jia Li, Zhenglu Wang, Liyun Zhang
  Analytica Chimica Acta.2026; 1394: 345209.     CrossRef
• Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD‐1 Inhibitor Plus TKIs in Combination of TACE for uHCC
  Houxiang Ya, Kai Wang, Huixia Qin, Yi Zhou, Hesheng Lin, Chengyuan Liu, Kaiwen Jiang, Jing Gu, Shuqun Li
  Liver International.2026;[Epub]     CrossRef
• Strategic drug sequencing in hepatocellular carcinoma in the era of chemo-diversity: maximizing the therapeutic benefit of lenvatinib
  Hideki Iwamoto, Shigeo Shimose, Hironori Koga, Takumi Kawaguchi
  Journal of Liver Cancer.2026; 26(1): 83.     CrossRef
• Radioonkologie bei hepatozellulärem Karzinom
  Eleni Gkika, Thomas Brunner, Lara Caglayan
  Die Onkologie.2026; 32(5): 458.     CrossRef
• Photo-triggered and magnetically guided nanosystems for precision drug transport: architecture development, spectral analysis and release behavior
  Feng Liu, Xing Peng, Yinghong Ling, Weizhi Tan, Mengjiao Huang, Tieyu Chen, Xiaohu Qin
  Frontiers in Nanotechnology.2026;[Epub]     CrossRef
• Liver transplantation is the major determinant of ≥10-year survival in patients with hepatocellular carcinoma
  Mohammad Saeid Rezaee-Zavareh, Joseph C. Ahn, Hyunseok Kim, Michael Luu, Walid Ayoub, Alexander Kuo, Hirsh Trivedi, Yun Wang, Aarshi Vipani, Tsuyoshi Todo, Georgios Voidonikolas, Justin A. Steggerda, Steven A. Wisel, Todd V. Brennan, Cristina Ferrone, Ire
  Hepatology Communications.2026;[Epub]     CrossRef
• Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with vascular invasion: A systematic review and meta‑analysis
  Yuhao Su, Yuxin Liang, Deyuan Zhong, Hongtao Yan, Qinyan Yang, Xiaolun Huang
  Oncology Letters.2026; 31(6): 1.     CrossRef
• Life as an editor-in-chief: somewhere between expectation and apprehension
  Seung Up Kim
  Science Editing.2026;[Epub]     CrossRef
• Factors associated with unmet psychological care needs and development of a Neuman systems model-based risk prediction model in patients with hepatocellular carcinoma
  Tong Wu, Qian Xu, Mugen Zhang
  Frontiers in Psychiatry.2026;[Epub]     CrossRef
• Interventional Radiology in the Management of Primary Liver Malignancies
  Kausthubh Hegde, Ronald Arellano, Shams Iqbal
  Cancers.2026; 18(14): 2283.     CrossRef
• Droplet Digital PCR Measurement of HBV DNA in On‐Treatment Chronic HBV Patients: Association With HCC Development and Outcomes
  Rex Wan‐Hin Hui, Danny Ka‐Ho Wong, James Fung, Ka‐Shing Cheung, Wai‐Kay Seto, Lung‐Yi Mak, Man‐Fung Yuen
  Journal of Viral Hepatitis.2026;[Epub]     CrossRef
• An artificial intelligence model for prediction of hepatocellular carcinoma risk in patients with chronic hepatitis C
  Yu Rim Lee, Hyunyeol Lee, Won Young Tak, Young Oh Kweon, Wonjun Son, Kyungsang Kim, Soo Young Park
  Scientific Reports.2026;[Epub]     CrossRef
• Comparison of Metastasectomy and Stereotactic Body Radiation Therapy for Pulmonary Oligometastasis From Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis
  Young Seob Shin, Jae Kwang Yun, Jinhong Jung, Jin-hong Park, Si Yeol Song, Eun Kyung Choi, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Geun Dong Lee, Sang Min Yoon
  International Journal of Radiation Oncology*Biology*Physics.2025; 121(2): 432.     CrossRef
• Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
  Bruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, Shukui Qin, Zhenggang Ren, Stephen L Chan, Yasuaki Arai, Jeong Heo, Anh Mai, Jose Escobar, Yamil Alonso Lopez Chuken, Jung-Hwan Yoon, Won Young Tak, Valeriy V Breder, Tanita Suttichaimongkol, Mohamed Bouatt
  The Lancet.2025; 405(10474): 216.     CrossRef
• Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”
  Moon Haeng Hur, Yoon Jun Kim
  Clinical and Molecular Hepatology.2025; 31(1): e93.     CrossRef
• APAGE Position Statements on Green and Sustainability in Gastroenterology, Hepatology, and Gastrointestinal Endoscopy
  Tiing Leong Ang, Dao Viet Hang, James Weiquan Li, Jacky Chiu Leung Ho, Marianne Linley Sy‐Janairo, Raja Affendi Raja Ali, Govind K. Makharia, Sridhar Sundaram, Tanyaporn Chantarojanasiri, Hyun‐Gun Kim, Hiroyuki Isayama, Nonthalee Pausawasdi, Kaichun Wu, A
  Journal of Gastroenterology and Hepatology.2025; 40(4): 821.     CrossRef
• Transarterial chemoembolization in hepatocellular carcinoma: exploring its role in vascular invasion and extrahepatic metastasis: A systematic review
  Muhammad Usman Younas, Abdullah Saeed, Muhammad Ramzan, Muhammad Junaid Tahir, Khabab Abbasher Hussien Mohamed Ahmed, Ali Ahmed
  Medicine.2025; 104(8): e41570.     CrossRef
• Plasma protein levels and hepatocellular carcinoma: a Mendelian randomization study with drug screening implications
  Longhui Xie, Dekun Song, Jianwei Lan, Pengpeng Liu, Shuang Qin, Yinkuan Ning, Quanyan Liu
  Discover Oncology.2025;[Epub]     CrossRef
• Quantitative Ablation Confirmation Methods in Percutaneous Thermal Ablation of Malignant Liver Tumors: Technical Insights, Clinical Evidence, and Future Outlook
  Iwan Paolucci, Jessica Albuquerque Marques Silva, Yuan-Mao Lin, Alexander Shieh, Anna Maria Ierardi, Gianpaolo Caraffiello, Carlo Gazzera, Kyle A. Jones, Paolo Fonio, Reto Bale, Kristy K. Brock, Marco Calandri, Bruno C. Odisio
  Radiology: Imaging Cancer.2025;[Epub]     CrossRef
• Long‐Term Survival and Prognostic Factors of Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Hepatocellular Carcinoma
  Hoang Dong Duc, Mai Binh Thanh, Mai Bang Hong, Nguyen Thinh Tien, Nguyen Thai Van, Bui Bieu Quang, Nguyen Chau Dinh, Thai Ky Doan
  Cancer Reports.2025;[Epub]     CrossRef
• Association between early job loss and prognosis among hepatocellular carcinoma survivors
  B Yun, J Oh, S H Ahn, B K Kim, J-H Yoon
  Occupational Medicine.2025; 75(2): 113.     CrossRef
• Spinal Cord Infarction After Transarterial Chemoembolization for Hepatocellular Carcinoma: A Case Report
  Tho Tran Dinh, Sy Than Van, Vinh Chu Van, Phuc Chu Minh
  Cureus.2025;[Epub]     CrossRef
• Imaging-based diagnosis of hepatocellular carcinoma: Liver Imaging Reporting and Data System and beyond
  Maryam Haghshomar, Andrea S Kierans, Laura Kulik, Frank H Miller, Amir A Borhani
  British Journal of Radiology.2025; 98(1173): 1344.     CrossRef
• Tumor size larger than 6.5 cm and microvascular invasion are comparable prognosticators for hepatocellular carcinoma: a multi-institutional observational study
  Hsing-Yu Chen, Hsin-I Tsai, Ming-Chin Yu, Wei-Chen Lee, Chih-Chi Wang, Jason Chia-Hsun Hsieh, Chiao-En Wu, Po-Ting Lin, Bo-Huan Chen, Sheng-Fu Wang, Chao-Wei Lee
  Clinical and Translational Oncology.2025; 28(1): 215.     CrossRef
• Outcome of hepatic resection for HCC in ideal and non-ideal candidates
  Lorenzo Lani, Laura Bucci, Valentina Santi, Benedetta Stefanini, Bernardo Stefanini, Angelo Sangiovanni, Sara Grasselli, Giorgia Ghittoni, Carlo Saitta, Filomena Morisco, Giuseppe Cabibbo, Fabio Marra, Gianpaolo Vidili, Maurizia Rossana Brunetto, Francesc
  Hepatology Communications.2025;[Epub]     CrossRef
• The construction and evaluation of a prognostic risk score model for HCC based on MPT-related lncRNAs
  Zerun Lin, Jianda Yu, Zhijian Chen, Jingyi Chen, Xiaobin Chi, Honghuan Lin, Yongbiao Chen
  Frontiers in Oncology.2025;[Epub]     CrossRef
• Serum Level of Glypican-3 in Patients with Hepatocellular Carcinoma and Advanced Chronic Liver Disease: A Pilot Study
  Irina Ivanova, Sonya Banova-Chakyrova, Pavlina Boykova-Vylcheva, Yana Bocheva
  Livers.2025; 5(3): 36.     CrossRef
• Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association
  Min-Su Park, Jai Young Cho, Eunju Kim, Hee Young Na, YoungRok Choi, Na Reum Ki, Young-In Yoon, Boram Lee, Eun Sun Jang, Yun Kyung Jung, Kyung Sik Kim
  Annals of Surgical Treatment and Research.2025; 109(3): 123.     CrossRef
• Machine Learning–Based Selection of Resection vs Transplant and Survival in Hepatocellular Carcinoma
  Hyun Uk Kim, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
  JAMA Network Open.2025; 8(9): e2532353.     CrossRef
• Public health strategies for hepatocellular carcinoma: from risk factors to prevention and control
  Mei-Hsuan Lee
  Journal of Liver Cancer.2025; 25(2): 204.     CrossRef
• Hepatocellular carcinoma: Epidemiology, diagnosis and treatment
  Ezequiel Mauro, Tiago de Castro, Marcus Zeitlhoefler, Max W. Sung, Augusto Villanueva, Vincenzo Mazzaferro, Josep M. Llovet
  JHEP Reports.2025; 7(12): 101571.     CrossRef
• A Patient Charter to Improve Care for Hepatocellular Carcinoma
  Yasmine Hassan, Achim Kautz, Cary James, Dee Lee, Diane Langenbacher, Eric Bouffet, Jade Chakowa, Jessica Hicks, John Ward, Lili Kuschnereit, Manon Allaire, Tingting Zhang, Zeena Huang Chi
  Journal of Hepatocellular Carcinoma.2025; Volume 12: 1849.     CrossRef
• Prognostic Role of Short-Chain Fatty Acid-Producing Gut Microbiota and Gut Microbial Dynamics in Patients with Hepatocellular Carcinoma Receiving Chemoembolization: A Prospective Study
  Jiwon Yang, Jihye Lim, Eun Hye Kim, Jihyun An, Danbi Lee, Han Chu Lee, Jin-Yong Jeong, Ju Hyun Shim
  Journal of Hepatocellular Carcinoma.2025; Volume 12: 1991.     CrossRef
• Immune Checkpoint Inhibitor Use in Advanced Hepatocellular Carcinoma: A Real-World Analysis of Efficacy and Toxicity
  Fode Tounkara, Deepak Sherpally, Khalid Mumtaz, Mina S. Makary, Russell F. Palm, Ashish Manne
  Cancers.2025; 17(18): 3034.     CrossRef
• Surgical treatment of hepatocellular carcinoma: an expert consensus-based practical recommendation from the Korean Liver Cancer Association
  Min-Su Park, Jai Young Cho, Eunju Kim, Hee Young Na, YoungRok Choi, Na Reum Kim, Young-In Yoon, Boram Lee, Eun Sun Jang, Yun Kyung Jung, Kyung Sik Kim
  Journal of Liver Cancer.2025; 25(2): 140.     CrossRef
• GALAD score accuracy in detection of hepatocellular carcinoma in cirrhotic patients: a single-center study
  Mina Tharwat, Yosra Yosry, Islam Nakeeb, Sahar Hassany
  The Egyptian Journal of Internal Medicine.2025;[Epub]     CrossRef
• Dynamic Muscle Atrophy Predicts Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Lenvatinib: A Retrospective Study in Taiwan
  Hsing-Yun Lee, Ching-Di Chang, Yen-Hao Chen, Ming-Chao Tsai, Jing-Houng Wang, Sheng-Nan Lu, Tsung-Hui Hu, Chao-Hung Hung, Chien-Hung Chen, Yuan-Hung Kuo
  Gut and Liver.2025; 19(6): 878.     CrossRef
• Decoding the epigenetic landscape: ctDNA methylation as a game-changer in hepatocellular carcinoma management
  Dexin Yang, Yueru Yao, Fenfang Gui, Wuxuan Mei, Changchun Zeng
  Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2025; 1880(6): 189497.     CrossRef
• Investigating Alternative Treatment Options Unfeasible for Local Ablation Therapy in Patients with Small Solitary Hepatocellular Carcinomas
  Chang Hun Lee, In Hee Kim
  Gut and Liver.2024; 18(1): 5.     CrossRef
• RNA 5-methylcytosine writer NSUN5 promotes hepatocellular carcinoma cell proliferation via a ZBED3-dependent mechanism
  Xinyu Gu, Penghui Li, Xiaohui Gao, Yi Ru, Chen Xue, Shujun Zhang, Yafeng Liu, Xinjun Hu
  Oncogene.2024; 43(9): 624.     CrossRef
• Letter regarding “Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study”
  Jongman Kim
  Journal of Liver Cancer.2024; 24(1): 3.     CrossRef
• Liver cancer surveillance in people with hepatitis B in Africa
  Dennis A Ndububa
  The Lancet Gastroenterology & Hepatology.2024; 9(6): 491.     CrossRef
• SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
  Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, Jae Youn Cheong
  Scientific Reports.2024;[Epub]     CrossRef
• Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of HCC
  Jong Geun Park, Pu Reun Roh, Min Woo Kang, Sung Woo Cho, Suhyun Hwangbo, Hae Deok Jung, Hyun Uk Kim, Ji Hoon Kim, Jae-Sung Yoo, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Young Kyoung You, Ho Joong Choi, Jae Yong Ryu, Pil Soo Sung
  Hepatology.2024; 80(5): 1074.     CrossRef
• Current perspectives of viral hepatitis
  Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou,
  World Journal of Gastroenterology.2024; 30(18): 2402.     CrossRef
• Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022
  Yuri Cho, Bo Hyun Kim, Young-Suk Lim
  Digestive Disease Interventions.2024; 08(03): 169.     CrossRef
• Research Progress on the Role of Epigenetic Methylation Modification in Hepatocellular Carcinoma
  Jing Wang, Wenyue Gao, Hongbo Yu, Yuting Xu, Changchuan Bai, Qingwei Cong, Ying Zhu
  Journal of Hepatocellular Carcinoma.2024; Volume 11: 1143.     CrossRef
• Establishment of nomogram prediction model of contrast-enhanced ultrasound and Gd-EOB-DTPA-enhanced MRI for vessels encapsulating tumor clusters pattern of hepatocellular carcinoma
  Feiqian Wang, Kazushi Numata, Akihiro Funaoka, Xi Liu, Takafumi Kumamoto, Kazuhisa Takeda, Makoto Chuma, Akito Nozaki, Litao Ruan, Shin Maeda
  BioScience Trends.2024; 18(3): 277.     CrossRef
• Limited Generalizability of Retrospective Single-Center Cohort Study in Comparison to Multicenter Cohort Study on Prognosis of Hepatocellular Carcinoma
  Ye Rim Kim, Sung Won Chung, Min-Ju Kim, Won-Mook Choi, Jonggi Choi, Danbi Lee, Han Chu Lee, Ju Hyun Shim
  Journal of Hepatocellular Carcinoma.2024; Volume 11: 1235.     CrossRef
• Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma
  Ji Yeon Lee, Pil Soo Sung
  Gut and Liver.2024; 18(4): 558.     CrossRef
• Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
  Lung-Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, Kuo Chao Yew, Nobuharu Tamaki, Ruveena Bhavani Rajaram, Mara Teresa Panlilio, Rashid Lui, Hye Won Lee, Jimmy Che-To Lai, Anand V. Kulkarni, Madhumita Premkumar, Cosmas Rinaldi Adithya Lesmana, Yao Chun Hsu,
  Nature Reviews Gastroenterology & Hepatology.2024; 21(12): 834.     CrossRef
• Liver resection and transplantation in the era of checkpoint inhibitors
  Parissa Tabrizian, Rebecca Marino, Pierce K.H. Chow
  JHEP Reports.2024; 6(11): 101181.     CrossRef
• Global epidemiology of liver cancer 2022: An emphasis on geographic disparities
  Qianru Li, Chao Ding, Maomao Cao, Fan Yang, Xinxin Yan, Siyi He, Mengdi Cao, Shaoli Zhang, Yi Teng, Nuopei Tan, Jiachen Wang, Changfa Xia, Wanqing Chen
  Chinese Medical Journal.2024; 137(19): 2334.     CrossRef
• Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity
  Mi Na Kim, Beom Kyung Kim, Heejin Cho, Myung Ji Goh, Yun Ho Roh, Su Jong Yu, Dong Hyun Sinn, Soo Young Park, Seung Up Kim, Tyng-Yuan Jang
  PLOS ONE.2024; 19(8): e0307712.     CrossRef
• Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment
  Jaejun Lee, Jong Young Choi, Soon Kyu Lee
  Journal of Liver Cancer.2024; 24(2): 253.     CrossRef
• A Nomogram Based on Features of Ultrasonography and Contrast-Enhanced CT to Predict Vessels Encapsulating Tumor Clusters Pattern of Hepatocellular Carcinoma
  Litao Ruan, Jingtong Yu, Xingqi Lu, Kazushi Numata, Dong Zhang, Xi Liu, Xiaojing Li, Mingwei Zhang, Feiqian Wang
  Ultrasound in Medicine & Biology.2024; 50(12): 1919.     CrossRef
• Prediction of PD-L1 expression in unresectable hepatocellular carcinoma with gadoxetic acid-enhanced MRI
  Jun Gu Kang, Kyunghwa Han, Taek Chung, Hyungjin Rhee
  European Journal of Radiology.2024; 181: 111772.     CrossRef
• Long-term outcomes of more than a decade treating patients with stereotactic body radiation therapy for hepatocellular carcinoma
  Wilhelm den Toom, Eva M. Negenman, Francois E.J.A. Willemssen, Erik van Werkhoven, Robert J. Porte, Roeland F. de Wilde, Dave Sprengers, Imogeen E. Antonisse, Ben J.M. Heijmen, Alejandra Méndez Romero
  Clinical and Translational Radiation Oncology.2024; 49: 100878.     CrossRef
• Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein throm
  Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon
  Clinical and Molecular Hepatology.2024; 30(4): 659.     CrossRef
• Combined Bone Mineral Density (BMD) and Monocyte-to-Lymphocyte Ratio (MLR) Predicts Recurrence and Prognosis in Hepatocellular Carcinoma Patients Following Liver Resection
  Ze-Jiao He, Tao Hu, Zi-Shu Zhang, Tian-Cheng Wang, Wei Huang
  Risk Management and Healthcare Policy.2024; Volume 17: 2741.     CrossRef
• Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances
  Gavin Wu, Nojan Bajestani, Nooruddin Pracha, Cindy Chen, Mina S. Makary
  Cancers.2024; 16(23): 3933.     CrossRef
• Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance
  Ali Gawi Ermi, Devanand Sarkar
  Cancers.2024; 16(23): 3944.     CrossRef
• Primary treatments for solitary hepatocellular carcinoma ≤ 3 cm: A systematic review and network meta-analysis
  Sang-Hoon Kim, Ki-Hun Kim, Byeong-Gon Na, Sung Min Kim, Rak-Kyun Oh
  Annals of Hepato-Biliary-Pancreatic Surgery.2024; 28(4): 397.     CrossRef
• TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation
  Yahui Zhang, Yidan Ren, Guoying Dong, Qinlian Jiao, Nan Guo, Ping Gao, Ya Li, Yunshan Wang, Wei Zhao
  Molecular Cancer Research.2024; 22(12): 1102.     CrossRef
• Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MRI improves diagnosis and efficacy evaluation of early-stage hepatocellular carcinoma
  Ya-Yun Wang
  American Journal of Cancer Research.2024; 14(10): 4855.     CrossRef
• Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma
  Hiroyuki Hakoda, Akihiko Ichida, Kiyoshi Hasegawa
  BioScience Trends.2024; 18(6): 525.     CrossRef
• Early-Stage HCC Percutaneous Locoregional Management: East versus West Perspectives
  Roberto Iezzi, Alessandro Posa, Andrea Contegiacomo, In Joon Lee, Reto Bale, Alessandro Tanzilli, Lorenzo Tenore, Felice Giuliante, Antonio Gasbarrini, Shraga Nahum Goldberg, Tobias Jakobs, Maurizio Pompili, Irene Bargellini, Evis Sala, Hyo-Cheol Kim
  Cancers.2023; 15(15): 3988.     CrossRef
• A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma
  Yun Bin Lee, Joon Yeul Nam, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Hyo-Cheol Kim, Jin Chul Paeng, Jung-Hwan Yoon, Yoon Jun Kim
  Clinical Cancer Research.2023; 29(18): 3650.     CrossRef
• Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?
  Hyo-Cheol Kim
  Clinical and Molecular Hepatology.2023; 29(4): 984.     CrossRef
• The efficacy of treatment for hepatocellular carcinoma in elderly patients
  Han Ah Lee, Sangheun Lee, Hae Lim Lee, Jeong Eun Song, Dong Hyeon Lee, Sojung Han, Ju Hyun Shim, Bo Hyun Kim, Jong Young Choi, Hyunchul Rhim, Do Young Kim
  Journal of Liver Cancer.2023; 23(2): 362.     CrossRef
• Multiomics characterization of fatty acid metabolism for the clinical management of hepatocellular carcinoma
  Xin Huang, Benzhe Su, Mengjun Li, Yang Zhou, Xinyu He
  Scientific Reports.2023;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Accurate prediction of HCC risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter
  Jimmy Che-To Lai, Anna S.F. Lok
  Hepatology.2026; 83(1): 11.     CrossRef
• Impact of Add‐On Hepatobiliary Abbreviated Magnetic Resonance Imaging on Ultrasound Hepatoma Surveillance for Liver Cirrhosis‐ a Randomized Study
  Jing‐Houng Wang, Hsin‐You Ou, Yi‐Hao Yen, Chao‐Hung Hung, Sheng‐Nan Lu
  The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
• Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-Male-Albumin-Bilirubin-Platelet (aMAP) and Liver Stiffness Assessed by Vibration-Controlled Transient Elastography
  Hye Yeon Chon, Hyung Joon Yim, Seok-Jae Heo, Su Jong Yu, Ja Kyung Kim, Sang Hoon Ahn, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip, Sang Gyune Kim, Yeon Seok Seo, Seung Up Kim
  Clinical Gastroenterology and Hepatology.2026; 24(7): 1897.     CrossRef
• Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression
  Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka
  Alimentary Pharmacology & Therapeutics.2026; 63(8): 1089.     CrossRef
• Association between deletions in the preS1/2 region of the hepatitis B virus genome and persistently abnormal ALT levels in patients with chronic hepatitis B treated with nucleos(t)ide analogs
  Yurina Sato, Kotaro Doi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Hirofumi Niitsuma, Atsushi Masamune
  Archives of Virology.2026;[Epub]     CrossRef
• Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis
  Juhee Ahn, Moon Haeng Hur, Hyunjae Shin, Min Kyung Park, Sungho Won, Jeayeon Park, Yunmi Ko, Youngsu Park, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
  Clinical and Molecular Hepatology.2026; 32(1): 339.     CrossRef
• Landscape of Somatic and Age‐Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long‐Read Sequencing
  Zhewen Wei, Yinghao Cao, Hongchao Liu, Mei Liu, Bolun Zhang, Jianming Ying, Jianqiang Cai, Xinyu Bi, Jianjun Zhao, Jianguo Zhou, Zhiyu Li, Zhen Huang, Jianmei Liu, Xueyan Lv, Zhiwen Luo, Zhicheng Wei, Xiaoshi Zhang, Yi Yang, Yiqiao Deng, Yanjiang Yin, Jin
  MedComm.2026;[Epub]     CrossRef
• Impact of cardiometabolic risk factors on hepatocellular carcinoma incidence in patients with chronic hepatitis B: A retrospective cohort study
  Chanavee Toh, Kedsiree Sanit, Pimsiri Sripongpun, Naichaya Chamroonkul, Suthat Liangpunsakul, Teerha Piratvisuth, Apichat Kaewdech, Samuel O. Antwi
  PLOS One.2026; 21(1): e0341366.     CrossRef
• Monitoring the activity of specific antibodies to pathogens based on biobank materials
  A. V. Nozdracheva, T. A. Semenenko, T. V. Ermakova, L. O. Kovtun
  Cardiovascular Therapy and Prevention.2026; 24(11): 4573.     CrossRef
• Very Low-density Lipoprotein-triacylglyceride Promotes Hepatitis B Virus Reactivation
  Cian-Ru Yang, Pei-Yin Liao, Wen-Jen Lin, Pei-Chun Shen, Ke Wang, Yu-Ting Su, Wei-Chung Cheng, Wei-Chun Chang, Jen-Chih Lee, Cheng-Yuan Peng, Hsueh-Chou Lai, Wen-Lung Ma
  Journal of Physiological Investigation.2026; 69(1): 68.     CrossRef
• HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management
  Yurou Jin, Chao Jin, Ronghui Xie, Jingming Zhang, Guangmin Wei, Ling Zheng
  Frontiers in Immunology.2026;[Epub]     CrossRef
• Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification
  Tai-Chung Tseng, Shang-Chin Huang, Jia-Horng Kao
  Hepatology Communications.2026;[Epub]     CrossRef
• Recurrence risk prediction model for hepatitis B virus-associated hepatocellular carcinoma patients: a systematic review and meta-analysis
  Ke-Hao Zhao, Jiajun Liu, Yun-Shan Chen, Wen-Ting Yi, Juan-Juan Liu, Ying Zeng
  Frontiers in Oncology.2026;[Epub]     CrossRef
• Analysis of HBV Genome Integration in Patients With HBV‐Previously Infected NBNC‐HCC
  Tomoya Saito, Rigel Suzuki, Akhinur Rahman, Kento Mori, Samiul Alam Rajib, Nobuhiro Kobayashi, Yoichi Yamamoto, Sharmin Nahar Sithi, Takaya Ichikawa, Tatsuya Orimo, Tatsuhiko Kakisaka, Lihan Liang, Naganori Nao, Saori Suzuki, Tomokazu Tamura, Yorifumi Sat
  Hepatology Research.2026; 56(7): 1101.     CrossRef
• Clinical utility of hepatitis B core-related antigen in chronic hepatitis B infection: diagnostic, prognostic, and therapeutic implications
  Bukhari Isah Shuaib, Usman Linda Itunu, Aminat Daud
  Egyptian Liver Journal.2026;[Epub]     CrossRef
• Establishment and characterization of a novel HBV-integrated hepatic sarcomatoid carcinoma cell line
  Jiayin Dai, Fang Cao, Zhenli Yang, Kun Dong, Xiaozheng Huang, Xiaocui Bian, Yuqin Liu
  Human Cell.2026;[Epub]     CrossRef
• Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications
  Wen Kang, Yu-Shen Liu, Tian-Ping Wang, Shu-Ming Zhang, Yu Li, Ye Zhang
  iLIVER.2026; 5(2): 100235.     CrossRef
• Predictors of HBV-associated hepatocarcinoma: a scientific review
  M. A. Lobanova, N. E. Danilova, S. S. Sleptsova, S. S. Sleptsov
  Yakut Medical Journal.2026; (2): 91.     CrossRef
• Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin‐3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
  Emi Sometani, Kazuhiro Murai, Hayato Hikita, Jihyun Sung, Satoshi Muraoka, Hidenori Toyoda, Satoshi Tanaka, Takayuki Miyake, Shinji Kuriki, Kenji Fukumoto, Satoshi Shigeno, Yuta Myojin, Kazuki Maesaka, Kumiko Shirai, Yuki Makino, Yuki Tahata, Yoshinobu Sa
  Hepatology Research.2026;[Epub]     CrossRef
• Hepatitis B core-related antigen as a multifaceted biomarker in chronic hepatitis B: implications for immune activity and hepatocellular carcinoma prediction
  Kwon Yong Tak, Seok Hwan Kim, Myeong Jun Song
  The Korean Journal of Internal Medicine.2026; 41(4): 636.     CrossRef
• Prediction of intrahepatic covalently closed circular DNA levels in patients with resolved hepatitis B virus infection: Impact of serum antibody to hepatitis B core antigen titers
  Sung Kwan Bae, Junichi Arita, Nobuhisa Akamatsu, Akihiko Ichida, Yujiro Nishioka, Akinori Miyata, Takuya Kawahara, Yoshinori Inagaki, Yoshikuni Kawaguchi, Junichi Kaneko, Sumihito Tamura, Yasuhito Tanaka, Hiroshi Yotsuyanagi, Kyoji Moriya, Kiyoshi Hasegaw
  Hepatology Research.2025; 55(4): 471.     CrossRef
• Liver elastography-based risk score for predicting hepatocellular carcinoma risk
  Chan Tian, Chunyan Ye, Haiyan Guo, Kun Lu, Juan Yang, Xiao Wang, Xinyuan Ge, Chengxiao Yu, Jing Lu, Longfeng Jiang, Qun Zhang, Ci Song
  JNCI: Journal of the National Cancer Institute.2025; 117(4): 761.     CrossRef
• Hepatitis B virus infection and its treatment in Eastern Ethiopia
  Tatsuo Kanda, Reina Sasaki-Tanaka, Atsunori Tsuchiya, Shuji Terai
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”
  Young-Joo Jin, Seung Up Kim
  Clinical and Molecular Hepatology.2025; 31(1): e55.     CrossRef
• Hepatic Iron Overload and Hepatocellular Carcinoma: New Insights into Pathophysiological Mechanisms and Therapeutic Approaches
  Elena Chatzikalil, Konstantinos Arvanitakis, Georgios Kalopitas, Matilda Florentin, Georgios Germanidis, Theocharis Koufakis, Elena E. Solomou
  Cancers.2025; 17(3): 392.     CrossRef
• Perceived HBV‐Related Stigma Is Associated With Lower Antiviral Medication Adherence in Patients With Chronic Hepatitis B
  Hee‐Soon Juon, Daniel Yang, Cindy Xin Fang, Hie‐Won Hann, Ho Bae, Mimi Chang, Ann C. Klassen
  Journal of Viral Hepatitis.2025;[Epub]     CrossRef
• Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
  Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
  Clinical and Molecular Hepatology.2025; 31(Suppl): S228.     CrossRef
• Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues
  Jun Inoue, Shinichiro Minami, Kazumichi Abe, Mami Kida, Hiroaki Haga, Chikara Iino, Hiroshi Numao, Hidekatsu Kuroda, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Takehiro Akahane, Tomoo Kobay
  Journal of Viral Hepatitis.2025;[Epub]     CrossRef
• Liver histological study of patients with chronic hepatitis B virus infection in the grey zone
  Weijia Lin, Rongrong Ding, Shuangshuang Sun, Wei Lu, Yanbin Wang, Xinlan Zhou, Dan Huang, Xiufen Li, Zhanqing Zhang, Liang Chen
  BMC Infectious Diseases.2025;[Epub]     CrossRef
• Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC
  Beom Kyung Kim
  Alimentary Pharmacology & Therapeutics.2025; 61(10): 1717.     CrossRef
• Statistical Cure After Hepatectomy for Hepatitis B Virus-Associated Hepatocellular Carcinoma: A Risk-Stratification Model
  Yi-Fan Li, Lan-Qing Yao, Chao Li, Hong Ren, Jin-Bo Gong, Han Wu, Li-Hui Gu, Ying-Jian Liang, Yu-Ze Yang, Kong-Ying Lin, Zi-Qiang Li, Qi-Xuan Zheng, Ting-Hao Chen, Ya-Hao Zhou, Hong Wang, Hong-Wei Guo, Jia-Hao Xu, Zhong Chen, Feng Shen, Ming-Da Wang, Tian
  Annals of Surgical Oncology.2025; 32(6): 4396.     CrossRef
• Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)
  Chung-Feng Huang, Jeong Heo, Rong-Nan Chien, Yang-Hyun Baek, Jia-Horng Kao, Ju-Hyun Kim, Ting-Tsung Chang, Kwan-Soo Byun, Jyh-Jou Chen, Sook-Hyang Jeong, Tsung-Hui Hu, Young-Seok Kim, Cheng-Yuan Peng, Won-Young Tak, Horng-Yuan Wang, Seung-Kew Yoon, I.-Shy
  Infectious Diseases and Therapy.2025; 14(5): 1089.     CrossRef
• Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
  Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
  Liver International.2025;[Epub]     CrossRef
• Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis
  Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K
  Journal of Gastroenterology and Hepatology.2025; 40(6): 1595.     CrossRef
• Hepatitis B core-related antigen as a predictive biomarker for recurrence in primary hepatocellular carcinoma: A meta-analysis
  Ling-Bo Liang, Hai-Jun Zhang, Feng Liu, Qiao-Li Su
  World Journal of Gastrointestinal Oncology.2025;[Epub]     CrossRef
• Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-α-2b-based therapy: a multicenter pilot study
  Li-Jun Chang, Chun-Qiu Hao, Gui-Rong Rao, Lin-Li Xu, Jing Li, Yan Cheng, Li-Jun Zheng, Cun-Wen Wu, Han-Xian Chen, Ze-Ren Chen, Jian-Qi Lian, Shi-Hong Wu, Li-Min Luo, Wei-Lu Zhang, Ye Zhang
  Virology Journal.2025;[Epub]     CrossRef
• Current and new strategies for hepatocellular carcinoma surveillance
  Natchaya Polpichai, Chongkonrat Maneenil, Pojsakorn Danpanichkul, Chitchai Rattananukrom, Ashok Choudhury, Yu Jun Wong, Pimsiri Sripongpun, Suthat Liangpunsakul, Apichat Kaewdech
  Gastroenterology Report.2025;[Epub]     CrossRef
• Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C
  Beom Kyung Kim
  Journal of Gastroenterology and Hepatology.2025; 40(8): 1855.     CrossRef
• RBP7 knockdown inhibits proliferation of human hepatocellular carcinoma and activates the p38 MAPK pathway
  Jinhai Li, Huawei Zhai, Fujing Cai, Xian Zhang, Yu Zhou, Shuqun Li, Huachun Song, Haifeng Zhang, Guangzheng Sun, Minghui Zhu, Jing Yuan, Ningxin Zhang, Maolin Yan
  Frontiers in Oncology.2025;[Epub]     CrossRef
• Prediction Model for Familial Aggregated HBV‐Associated Hepatocellular Carcinoma Based on Serum Biomarkers
  Linmei Zhong, Guole Nie, Qiaoping Wu, Honglong Zhang, Haiping Wang, Jun Yan
  Cancer Reports.2025;[Epub]     CrossRef
• Predictive Value of Hepatitis B Core-Related Antigen for Multiple Recurrence Outcomes After Treatment Cessation in Chronic Hepatitis B: A Meta-Analysis Study
  Guoyang Yu, Meiqi Cheng, Yuxin Duan, Minrong Kang, Ning Jiang, Wei Yan, Jianhua Yin
  Viruses.2025; 17(7): 929.     CrossRef
• Evaluating serum extra spindle pole bodies-like 1 protein vs p53 antibody for hepatitis B virus-related hepatocellular carcinoma diagnosis
  Yan-Fei Feng, Hui-Kun Zhou, Bo-Bin Hu, Hang Wang, Heng-Kai Liang, Lu Wei, Qing-Mei Li, Tu-Mei Su, Qian-Bing Yin, Ming-Hua Su, Jian-Ning Jiang
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis
  Yunmi Ko, Byeong Geun Song, Hyunjae Shin, Youngsu Park, Jeayeon Park, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Dong Hyun Sinn, Yoon Jun Kim, Jung-Hwan Yoon, Seung Shin Park, Moon Haeng Hur, Jeong-Hoon Lee
  Osteoporosis International.2025; 36(8): 1391.     CrossRef
• Clinical Features of HBV‐Related HCC in Long‐Term NAs‐Treated Versus Untreated Patients
  Yuyu Ye, Yeqiong Zhang, Yunming Tang, Ming Liu, Shibin Xie, Ying Liu
  Journal of Cellular and Molecular Medicine.2025;[Epub]     CrossRef
• Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
  Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim
  Scientific Reports.2025;[Epub]     CrossRef
• Postoperative immune checkpoint inhibitors plus anti-angiogenesis for hepatitis B virus-associated hepatocellular carcinoma: Analyzing the evidence and future prospects
  Arunkumar Krishnan, Diptasree Mukherjee
  World Journal of Gastrointestinal Oncology.2025;[Epub]     CrossRef
• A machine learning model for non-invasive prediction of advanced liver fibrosis in patients with chronic hepatitis B
  Jingwei Song
  American Journal of Translational Research.2025; 17(7): 4939.     CrossRef
• Prognostic significance of systemic immune-inflammation index in hepatocellular carcinoma: a meta-analysis
  Zhi Li, Juan Luo, Lihua Peng, Bangqiang Wu, Zebo Yu
  Clinical and Translational Oncology.2025; 28(2): 601.     CrossRef
• Flotillin-1 promotes the progression of hepatocellular carcinoma by activating TFE3-mediated Golgi stress response via inhibition of mTORC1/2
  Liang Zhang, Cheng-Zhi Bai, Jia-Yan Shan, Hong-Li Xue, Shu-Mei Zheng, Ya-Lun Chen, Shan-Hong Tang
  World Journal of Gastroenterology.2025;[Epub]     CrossRef
• Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure—Editorial on “Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B”
  Soon Kyu Lee
  The Korean Journal of Gastroenterology.2025; 85(3): 245.     CrossRef
• Hepatitis B virus integration and hepatocarcinogenesis
  Linlin Ma, Shuzhen Chen, Hongyang Wang, Lei Chen
  Liver Research.2025; 9(3): 189.     CrossRef
• Machine learning-based hepatocellular carcinoma risk prediction model for patients with HBV-related compensated advanced chronic liver disease
  Yanqiu Li, Zihang Qiao, Yongqi Li, Ying Feng, Xianbo Wang
  Journal of Cancer Research and Clinical Oncology.2025;[Epub]     CrossRef
• ‘What is new in hepatitis B’
  Upkar S Gill, Victoria J Appleby, Sabela Lens
  Frontline Gastroenterology.2025; : flgastro-2024-102850.     CrossRef
• Global strategies and actions to eliminate hepatitis B virus infection
  Chih-Lin Lin, Jia-Horng Kao
  Clinical and Molecular Hepatology.2025; 31(4): 1197.     CrossRef
• Hepatocellular carcinoma: modern aspects of interdisciplinary management. Part 1. Epidemiology, risk factors, diagnosis
  Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova
  GASTROENTEROLOGY.2025; 59(3): 206.     CrossRef
• Assessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers?
  Deniz Borcak, Zuhal Yesilbag, Yusuf Emre Ozdemir, Adile Sevde Demir, Esra Salim Dogdas, Aysegul Inci Sezen, Esra Canbolat Unlu, Sevtap Senoglu, Hayat Kumbasar Karaosmanoglu, Kadriye Kart Yasar
  Journal of Clinical Medicine.2025; 14(22): 8164.     CrossRef
• Hepatitis B virus X protein promotes the progression and immune escape of hepatocellular carcinoma by activating KLF16-C12orf49-PD-L1 axis
  Wenbiao Chen, Chenhong Lin, Luolin Wang, Zhichao Yu, Yuxiuxiu Xu, Minhai Zhang, Lisheng Wang, Jun Yao
  Oncogene.2025; 44(48): 4747.     CrossRef
• Insilico evaluation of the therapeutic effects of N1-(5-(3-imino-2,4a-dihydro-3H-benzo[f]chromen-2-yl)-1,3,4-thiadiazol-2-yl)-N10-(5-(3-imino-3H-benzo[f]chromen-2-yl)-1,3,4-thiadiazol-2-yl)decanediamide as Anti-Hepatitis B and C agent
  Moses M. Edim, Njok N. Okam, Nguuma I. Gber, Jessica E. Egbelo, Israel E. Okon, Chiemerie P. Ogbonna, Emmanuel K. Aidoo, Kenneth N. Chisom, Emmanuel Samuel
  Polytechnic Journal.2025;[Epub]     CrossRef
• Effects of Citrus depressa Hayata juice on high-fat diet-induced obesity in HBV transgenic mice
  Pei-Yi Chu, Chang-Lu Hsu, Yen-An Lin, Yi-Cheng Pan, Yun-Hao Dai, Ying-Chun Yu, Juan-Cheng Yang, Wen-Lung Ma, Yi-Jinn Lillian Chen, Chia-Lin Lee, Yang-Chang Wu
  Heliyon.2024; 10(2): e24438.     CrossRef
• Precision Management of Patients with HBV Infection
  Chih-Lin Lin, Jia-Horng Kao
  Current Hepatology Reports.2024; 23(1): 22.     CrossRef
• Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy
  Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Sang Hoon Ahn, Won Kim, Jin Mo Yang, Jae Young Jang, Yong Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Joo Hyun Sohn, Jin Woo Lee, Sung Jae Park, Sun Young Yim, Jin Kyung Park, Soon
  Cancers.2024; 16(5): 887.     CrossRef
• Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma
  Nevin Varghese, Amry Majeed, Suraj Nyalakonda, Tina Boortalary, Dina Halegoua-DeMarzio, Hie-Won Hann
  Cancers.2024; 16(4): 777.     CrossRef
• Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients
  Chinmay Bera, Nashla Hamdan-Perez, Keyur Patel
  Journal of Clinical Medicine.2024; 13(4): 1046.     CrossRef
• Validation of the Texas Hepatocellular Carcinoma Risk Index Predictive Model for Hepatocellular Carcinoma in Asian Cohort
  Jeong-Ju Yoo, Young-Gi Song, Ji Eun Moon, Young Seok Kim, Sang Gyune Kim
  Clinical Gastroenterology and Hepatology.2024; 22(9): 1953.     CrossRef
• Research Progress of Pegylated Interferon Therapy for Chronic HBV Infection
  巧霞 陈
  Advances in Clinical Medicine.2024; 14(03): 1605.     CrossRef
• Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB
  Shaowen Jiang, Simin Guo, Yan Huang, Jie Xu, Yi Li, Yilan Zeng, Yuan Guo, Lijuan Ouyang, Chuanwu Zhu, Weifeng Zhao, Qin Zhang, Qing Guo, Haiguang Xin, Qing Xie
  Antiviral Research.2024; 226: 105892.     CrossRef
• Role of hepatitis B core‐related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta‐analysis
  Qi‐Hang Cao, Hui Liu, Lun‐Jie Yan, Han‐Chao Wang, Zi‐Niu Ding, Xin‐Cheng Mao, Rui‐Zhe Li, Guo‐Qiang Pan, Xiao Zhang, Bao‐Wen Tian, Cheng‐Long Han, Zhao‐Ru Dong, Si‐Yu Tan, Dong‐Xu Wang, Yu‐Chuan Yan, Tao Li
  Journal of Gastroenterology and Hepatology.2024; 39(8): 1464.     CrossRef
• Machine learning-based model for predicting tumor recurrence after interventional therapy in HBV-related hepatocellular carcinoma patients with low preoperative platelet-albumin-bilirubin score
  Qi Wang, Shugui Sheng, Yiqi Xiong, Ming Han, Ronghua Jin, Caixia Hu
  Frontiers in Immunology.2024;[Epub]     CrossRef
• Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do
  Walaa Abdelhamed, Mohamed El-Kassas
  Liver Research.2024; 8(2): 83.     CrossRef
• Predictive Risk Factors and Scoring Systems Associated with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B
  Ploutarchos Pastras, Evaggelos Zazas, Maria Kalafateli, Ioanna Aggeletopoulou, Efthymios P. Tsounis, Stavros Kanaloupitis, Konstantinos Zisimopoulos, Eirini-Eleni-Konstantina Kottaridou, Aspasia Antonopoulou, Dimosthenis Drakopoulos, Georgia Diamantopoulo
  Cancers.2024; 16(14): 2521.     CrossRef
• Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
  Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon
  Clinical and Molecular Hepatology.2024; 30(3): 500.     CrossRef
• Risk predictive model for the development of hepatocellular carcinoma before initiating long‐term antiviral therapy in patients with chronic hepatitis B virus infection
  Junjie Chen, Tienan Feng, Qi Xu, Xiaoqi Yu, Yue Han, Demin Yu, Qiming Gong, Yuan Xue, Xinxin Zhang
  Journal of Medical Virology.2024;[Epub]     CrossRef
• The unfolded features on the synchronized fashion of gut microbiota and Drynaria rhizome against obesity via integrated pharmacology
  Ki-Kwang Oh, Sang-Jun Yoon, Seol Hee Song, Jeong Ha Park, Jeong Su Kim, Min Ju Kim, Dong Joon Kim, Ki-Tae Suk
  Food Chemistry.2024; 460: 140616.     CrossRef
• M2BPGi Correlated with Immunological Biomarkers and Further Stratified Recurrence Risk in Patients with Hepatocellular Carcinoma
  I-Cheng Lee, Hao-Jan Lei, Lei-Chi Wang, Yi-Chen Yeh, Gar-Yang Chau, Cheng-Yuan Hsia, Shu-Cheng Chou, Jiing-Chyuan Luo, Ming-Chih Hou, Yi-Hsiang Huang
  Liver Cancer.2024; : 1.     CrossRef
• Beta‐caryophyllene attenuates experimental hepatocellular carcinoma through downregulation of oxidative stress and inflammation
  Zaved Ahmad, Subodh Kumar Jain, Siddhartha Kumar Mishra
  Journal of Biochemical and Molecular Toxicology.2024;[Epub]     CrossRef
• The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment
  Wencong Zhang, Jia Chen, Wenjin Sun, Nana Xie, Fangbing Tian, Qiurong Ruan, Jianxin Song
  Virology Journal.2024;[Epub]     CrossRef
• Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis
  Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi
  Clinical and Molecular Hepatology.2024; 30(Suppl): S106.     CrossRef
• Chronic hepatitis B: Prevent, diagnose, and treat before the point of no return
  Sudheer Marrapu, Ramesh Kumar
  World Journal of Hepatology.2024; 16(10): 1151.     CrossRef
• Chronic hepatitis B: Prevent, diagnose, and treat before the point of no return
  Sudheer Marrapu, Ramesh Kumar
  World Journal of Hepatology.2024; 16(10): 1331.     CrossRef
• Chronic Hepatitis B Genotype C Mouse Model with Persistent Covalently Closed Circular DNA
  Deok-Hwa Seo, Wonhee Hur, Juhee Won, Ji-Won Han, Seung-Kew Yoon, Songmee Bae, Kyun-Hwan Kim, Pil-Soo Sung
  Viruses.2024; 16(12): 1890.     CrossRef
• Test All for Hepatitis B Virus
  Katerina Roma, Zahra Dossaji, Lubaba Haque, Tooba Laeeq, Robert G. Gish, Carol Brosgart
  Clinics in Liver Disease.2023; 27(4): 997.     CrossRef
• Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients
  Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Xuehong Zhang, Sang Hoon Ahn
  International Journal of Cancer.2023; 153(8): 1448.     CrossRef
• Evidence-Based Strategies for Micro-elimination of Chronic Hepatitis B Virus Infection
  Katerina Roma, Mark Hsu, Adam Khattak, Robert Gish
  Current Hepatology Reports.2023; 22(3): 118.     CrossRef

Citations

Citations to this article as recorded by  

• Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”
  Jeong-Ju Yoo, Sang Gyune Kim
  Clinical and Molecular Hepatology.2023; 29(2): 513.     CrossRef

Citations

Citations to this article as recorded by  

• Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure
  Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen
  Gut.2026; 75(1): 119.     CrossRef
• Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression
  Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka
  Alimentary Pharmacology & Therapeutics.2026; 63(8): 1089.     CrossRef
• Targeting the innate immune system in treating hepatitis B: prospects for functional cure
  Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
  Clinical and Molecular Hepatology.2026; 32(1): 184.     CrossRef
• Hepatitis B virus RNA and hepatitis B surface antigen kinetics predict treatment outcomes in children with chronic hepatitis B
  Xiaorong Peng, Yunan Chang, Jiaying Wu, Jing Zhu, Peng Hu, Hong Ren, Hongmei Xu, Ruiqiu Zhao, Tao Qin
  Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
• Clinical Trials for Curing Chronic Hepatitis B: A Comprehensive Analysis of Trial Design Considerations and Their Association With Trial Performance
  Lichen Shi, Hao Wang, Cheng Huang, Yifan Du, Hong You, Jidong Jia, Yuanyuan Kong
  Journal of Gastroenterology and Hepatology.2026; 41(5): 1389.     CrossRef
• Implementation of quantitative HBsAg testing in clinical microbiology laboratories in Spain: Results from a national GEHEP-SEIMC survey
  Lucía Chaves-Blanco, Marta Illescas-López, Ana Fuentes, Raquel Carracedo, Alberto Delgado-Iribarren, Alberto Vázquez Blanquiño, Ana María Blázquez, Ruth Sáez, Ana Miqueleiz, María de los Reyes Vidal, Tomás Tosco, César Gómez, Luz Moldes, Noelia Calvo, Luc
  Enfermedades Infecciosas y Microbiología Clínica.2026; 44(7): 503215.     CrossRef
• Superior Efficacy of Besifovir in Reducing Hepatocellular Carcinoma Risk Compared to Tenofovir in Chronic Hepatitis B Patients: A Nationwide Cohort Study
  Yoon E Shin, Jae Young Kim, Hyuk Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim
  Journal of Korean Medical Science.2026;[Epub]     CrossRef
• Droplet Digital PCR Measurement of HBV DNA in On‐Treatment Chronic HBV Patients: Association With HCC Development and Outcomes
  Rex Wan‐Hin Hui, Danny Ka‐Ho Wong, James Fung, Ka‐Shing Cheung, Wai‐Kay Seto, Lung‐Yi Mak, Man‐Fung Yuen
  Journal of Viral Hepatitis.2026;[Epub]     CrossRef
• Implementation of quantitative HBsAg testing in clinical microbiology laboratories in Spain: Results from a national GEHEP-SEIMC survey
  Lucía Chaves-Blanco, Marta Illescas-López, Ana Fuentes, Raquel Carracedo, Alberto Delgado-Iribarren, Alberto Vázquez Blanquiño, Ana María Blázquez, Ruth Sáez, Ana Miqueleiz, María de los Reyes Vidal, Tomás Tosco, César Gómez, Luz Moldes, Noelia Calvo, Luc
  Enfermedades infecciosas y microbiologia clinica (English ed.).2026; 44(7): 503215.     CrossRef
• Investigational RNA Interference Agents for Hepatitis B
  Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
  BioDrugs.2025; 39(1): 21.     CrossRef
• Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure
  Yue Qiu, Qiao Tang, Xiao-Qing Liu, Yun-Ling Xue, Yi Zeng, Peng Hu
  World Journal of Hepatology.2025;[Epub]     CrossRef
• Prospect of emerging treatments for hepatitis B virus functional cure
  Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
  Clinical and Molecular Hepatology.2025; 31(Suppl): S165.     CrossRef
• Development and Validation of a High‐Sensitivity Droplet Digital PCR Assay for Serum Hepatitis B Virus DNA Detection
  Rex Wan‐Hin Hui, Danny Ka‐Ho Wong, Lung‐Yi Mak, James Fung, Wai‐Kay Seto, Man‐Fung Yuen
  Journal of Viral Hepatitis.2025;[Epub]     CrossRef
• Functional Cure for Hepatitis B Virus: Challenges and Achievements
  Oren Shechter, Daniel G. Sausen, Harel Dahari, Andrew Vaillant, Scott J. Cotler, Ronen Borenstein
  International Journal of Molecular Sciences.2025; 26(8): 3633.     CrossRef
• Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters
  Lung-Yi Mak, Mark Anderson, Michael Stec, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, Rex Wan-Hin Hui, Wai-Kay Seto, Gavin Cloherty, Man-Fung Yuen
  Clinical and Molecular Hepatology.2025; 31(2): 460.     CrossRef
• Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study
  Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani
  Health Science Reports.2025;[Epub]     CrossRef
• Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies
  Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
  Hepatology International.2025; 19(4): 704.     CrossRef
• Simplified flow cytometry-based assay for rapid multi-cytokine profiling and machine-learning-assisted diagnosis of inflammatory diseases
  Qiang Quan, Xuegui Ju, Guangmei Li, Lu Ye, Sichong Ren, Shuxin Yang, Rui Zhang, Hui Wang, Ruyue Lin, Luoting Yu
  Frontiers in Pharmacology.2025;[Epub]     CrossRef
• Prise en charge du porteur de l’antigène HBs
  F.H. Pujol, R. Jaspe, C. Trépo, I. Chemin
  EMC - Hépatologie.2025; 40(4): 1.     CrossRef
• Challenges and advances in clinical cure of chronic hepatitis B
  Xu-Ling Liu, Yu-Lang Jiang, Ming-Yu Sun
  World Chinese Journal of Digestology.2025; 33(9): 693.     CrossRef
• Hepatitis B Surface Antigen Isoforms: Their Clinical Implications, Utilisation in Diagnosis, Prevention and New Antiviral Strategies
  Ivana Lazarevic, Ana Banko, Danijela Miljanovic, Maja Cupic
  Pathogens.2024; 13(1): 46.     CrossRef
• ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B
  Ryan Hin-Man Leung, Rex Wan-Hin Hui, Lung-Yi Mak, Xianhua Mao, Kevin Sze-Hang Liu, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Man-Fung Yuen
  Journal of Hepatology.2024; 81(2): 218.     CrossRef
• Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis
  Hyunjae Shin, Won-Mook Choi, Seung Up Kim, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Fabien Zoulim
  JHEP Reports.2024; 6(7): 101089.     CrossRef
• Linvencovir: Paving the way for functional cure in hepatitis B
  Jiwon Yang, Jonggi Choi
  Clinical and Molecular Hepatology.2024; 30(2): 164.     CrossRef
• Editorial: High qHBsAg—is it a good or bad signal?
  Beom Kyung Kim
  Alimentary Pharmacology & Therapeutics.2024; 59(12): 1616.     CrossRef
• Role of hepatitis B core‐related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta‐analysis
  Qi‐Hang Cao, Hui Liu, Lun‐Jie Yan, Han‐Chao Wang, Zi‐Niu Ding, Xin‐Cheng Mao, Rui‐Zhe Li, Guo‐Qiang Pan, Xiao Zhang, Bao‐Wen Tian, Cheng‐Long Han, Zhao‐Ru Dong, Si‐Yu Tan, Dong‐Xu Wang, Yu‐Chuan Yan, Tao Li
  Journal of Gastroenterology and Hepatology.2024; 39(8): 1464.     CrossRef
• Current perspectives of viral hepatitis
  Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou,
  World Journal of Gastroenterology.2024; 30(18): 2402.     CrossRef
• Extended analysis on peripheral blood cytokines correlated with hepatitis B virus viral load in chronically infected patients – a systematic review and meta-analysis
  Marina Manea, Ion Mărunțelu, Ileana Constantinescu
  Frontiers in Medicine.2024;[Epub]     CrossRef
• Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
  Cho-Rong Lee, Sung-Gyoo Park
  Clinical and Molecular Hepatology.2024; 30(4): 724.     CrossRef
• Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B pati
  Beom Kyung Kim
  Clinical and Molecular Hepatology.2024; 30(4): 656.     CrossRef
• CD4+ T cell counts and soluble programmed death-1 at baseline correlated with hepatitis B surface antigen decline in HIV/HBV coinfection during combined antiretroviral therapy
  Xiaodi Li, Ling Xu, Lianfeng Lu, Xiaosheng Liu, Yang Yang, Yuanni Wu, Yang Han, Xiaoxia Li, Yanling Li, Xiaojing Song, Wei Cao, Taisheng Li
  Frontiers in Cellular and Infection Microbiology.2023;[Epub]     CrossRef
• Opportunities and challenges for hepatitis B cure
  Armando Andres Roca Suarez, Fabien Zoulim
  eGastroenterology.2023; 1(2): e100021.     CrossRef
• Non-Invasive Prediction Scores for Hepatitis B Virus- and Hepatitis D Virus-Infected Patients—A Cohort from the North-Eastern Part of Romania
  Laura Iulia Grecu, Camelia Sultana, Mariana Pavel-Tanasa, Simona Maria Ruta, Mihaela Chivu-Economescu, Lilia Matei, Ramona Gabriela Ursu, Elena Iftimi, Luminita Smaranda Iancu
  Microorganisms.2023; 11(12): 2895.     CrossRef

Citations

Citations to this article as recorded by  

• Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”
  Su Bin Lim, Hyo Jung Cho
  Clinical and Molecular Hepatology.2024; 30(4): 1009.     CrossRef